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ABSTRACT

Cattle, naturally infected with Mycobacterium
paratuberculosis. were evaluated with respect to immune
status.

Their ability to express cell mediated immune

responses to homologous and heterologous antigens was
also evaluated.

Lymphocyte and macrophage augmentation was

attempted to localize the immune defect in cattle with
paratuberculosis.
Infected cattle had varying responses to johnin skin
test antigen.

Lymphocyte blastogenic responses and

migration inhibition were, however, consistently positive
in infected cattle.

Non-infected cattle had positive

skin test reactions, blastogenic responses, and migration
inhibition after sensitization with M^ bovis BCG, M.
paratuberculosis. and keyhole limpet hemocyanin.

No

changes were seen in lymphocyte blastogenic response,
migration inhibition, interleukin-2 production, and
interleukin-1 release in infected cattle after
sensitization.
Rifabutin treatment increased cutaneous
hypersensitivity to johnin skin test antigen.

No lesion

alterations were induced with this antimicrobial
agent.

Preliminary evidence indicated that blood monocytes
phagocytize bacteria and take up ferritin.

It could not be

accurately determined if killing of the organism had
taken place.

The ferritin was seen in round clumps

suggestive of secondary lysosomes and as small grains in
association with bacteria.

This may have represented

phagosome-lysosome fusion.

Interleukin-2 production

was decreased in infected cattle from that in non
infected controls.

Non-infected cattle significantly

increased interleukin-2 production in response to
sensitizing antigens while no effect was seen in the
infected animals.
Transfer factor specific for tL paratuberculosis and
keyhole limpet hemocyanin augmented cell-mediated
responses in infected cattle as evidenced by positive
migration inhibition and increased interleukin-2
production.

No alterations in ileal and mesenteric lymph

node lesions were noted after transfer factor treatment.
Blood monocytes from infected cattle spontaneously
released high levels of interleukin-1 and increased
release with bacterial lipopolysaccharide stimulation.
Non-infected cattle released significant levels with
keyhole limpet hemocyanin, M;_ bovis PPD, and johnin with
the highest release occurring with johnin stimulation.

x

Interleukin-1 release was not affected by sensitization
with

bo vis BCG, Mj_ paratuberculosis and

keyhole limpet hemocyanin.

CHAPTER 1

LITERATURE REVIEW AND OBJECTIVES
General
Bovine paratuberculosis is a chronic debilitating
enteric infection of ruminants caused by the acid-fast
bacillus Mycobacterium paratuberculosis.

The disease was

first described by Johne and Frothingham in 1895,1 hence
the name, Johne's disease.

The organism was first

isolated by Twort in 19102,3 and became named
Mycobacterium enteriditis chronicae pseudotuberculosae
bovis johne.

The disease later became known as

paratuberculosis or Johne's disease and the causative
agent became Mycobacterium paratuberculosis.
Paratuberculosis occurs throughout the world and
has a relatively wide host range.

In addition to sheep

and goats, numerous species of wildlife,4,5,6,7,8,9,10,11
exotic animals,12,13,14,15,16,17,18,19,20 and nonconventional domestic animals17,21,22 have been infected.
Monogastrics may also become infected under special
circumstances.23-28

The organism may multiply in these

hosts, but rarely results in clinical disease.

The

implication remains, however that these hosts may serve

1

as a reservoir for ruminant infection.
Paratuberculosis was first described in North
America m

1908^

and has since been observed in

virtually every state.

A 1983 abattoir survey of 1000

cattle in Wisconsin showed histologic lesions of Johne's
disease in 11% of the animals examined. 3(^

In a New

England-based study a prevalence rate of 18% was shown by
employing culture techniques in addition to histologic
qi
evaluation. ^ It was concluded that histologic
evaluation alone was too inaccurate and insensitive.

In

a recent nationwide survey of 32 states and Puerto Rico,
non
Merkal et al^i£ examined lymph node specimens from 7,540
animals by culture methods and found an overall
prevalence of bovine paratuberculosis of 1.6%.

The

prevalence in dairy and beef cattle was determined to be
2.9% and 0.8%, respectively.

It has been estimated that

losses for the dairy industry in the United States exceed
$1.5 billion per y e a r . 3 ^
Animals are usually infected at less than 30 days of
age and evidence by experimental inoculation suggested
that cattle must become infected during calfhood in order
to develop clinical disease because of the development of
age-related resistance.33-43

It is estimated that only

one-third of the exposed animals ever become infected.44
Development of disease is dependent on the size of the
exposure dose and the immunologic status of the host.44

Animals infected as adults may develop less obvious
lesions or eliminate the organism.44

Experimentally

infected animals have been reported to
recover.37'43 '4 5 '46

Some animals exposed to the organism

never develop clinical disease, but may become carriers
and shedders of the organism.44
The Channel Island and Shorthorn breeds appear to
have the greatest incidence of infection among cattle.47
In Louisiana, however, the Brahman is frequently
infected.

This may be simply due to the larger number of

Brahman and Brahman-cross cattle in Louisiana versus
Channel Island breeds.
Ingestion of feces containing high number of bacteria
AO

is the primary source of infection for the neonate. °
Once ingested the organism

penetrates the intestinal

mucosa through Peyer's patches.4^-51,225

o r g a n j_s m

is

then phagocytized by macrophages and survives
intracellularly where it is protected from humoral
factors.

A multifocal to diffuse granulomatous lesion

develops in the intestine and regional lymph nodes.
Terminally a bacteremia and anergy develops.44
Bacteremia can also develop in infected animals by
desensitization

with johnin.52

The organism has been

recovered from testes,53 semen,53-55 bulbourethral
gland,54 prostate,5 4 '55 seminal vesicles,54'55 mammary
gland,57-59 uterus,5 8 '60-62 and the fetus.61-64

Because

of these observations, congenital infections have been
postulated.

However, in a study by Merkal et al.,65 75%

of infected animals within a herd came from noninfected
dams.

During anergy, the organism may invade the

cotyledons and result in abortion.66

Transuterine

infection with subsequent development of paratuberculosis
has not been documented.44

As many as 7% of infected

animals shed the organism in the m i l k . ^ '66•

This may

also serve as a significant source of infection in young
animals in addition to contaminated feces which may
ft

contain greater the 10° organisms per gram.
Paratuberculosis is a slow spreading disease
requiring an extended period of time for the development
of clinical signs.

Herds consequently become infected

before the disease is recognized in individual animals.
It has been shown that by the time the first infected
animal is recognized, 38%-42% of the herd is infected.6770

Annual death losses within a herd may be as high as

3%-10%.

Clinical disease is usually associated with

adult (>2 years) animals, however clinical disease has
been seen in animals as young as 4 months of age.7-1Parturition, a low plane of nutrition, high milk
production, parasitic infection, grazing on mineraldeficient low lying wetlands, and various other stress
factors have been incriminated in precipitating clinical
disease.7^-76

Clinical Signs
Clinical signs usually begin as a nonresponsive,
chronic or intermittent diarrhea.

Periods of apparent

remission occur which may last for weeks or months.
Diarrhea subsides and weight gains occur during
pregnancy, however at parturition diarrhea resumes,
often more severe than previously.^

There may be

intermittent fever, however appetite is usually

good.

During the terminal stages of the disease the diarrhea
may become bloody, there is loss of appetite, emaciation,
ventral edema, and death.
It has long been known that clinical signs and the
severity of the lesions rarely correspond.

71 —7 6

In

cattle the lesion is characterized as a diffuse
granulomatous change, without necrosis, hyperemia, or
reactionary fibrosis.76-79

Primary lesions are confined

to the intestinal tract and regional lymph nodes, but
there may be effusion into body cavities, serous atrophy
of fat, and subcutaneous edema in the dependent areas of
the carcass.

The intestine is usually thickened,

corrugated and highly folded.
segments of gut are stretched.

The folds remain when the
In animals infected with

pigmented strains of Mycobacterium paratuberculosis the
intestinal mucosa may take on a yellow-orange hue.79-6^
Lesions may be found from the duodenum to rectum, but are

most common in the terminal ileum.

In younger animals

there may be no intestinal thickening, instead a
0*3

hemorrhagic enteritis occurs. J

In regional mesenteric

lymph nodes there is a granulomatous lymphadenitis with
marked lymph node enlargement.
also be prominent.

Mesentric lymphatics may

Lesions occasionally occur in other

organs with the liver being the most common secondary
organ affected.7 6 '84

Pathology
Histologically the affected intestine contains
numerous foamy macrophages within the lamina propria and
occasionally in the submucosa.

Early lesions appear

tuberculoid (nodular) and rapidly coalesce to become
lepromatous (diffuse).44

Langhans' type giant cells may

or may not be a prominent feature.

Acid-fast stains

reveal the presence of numerous bacilli within the
macrophages and giant cells.

Occasionally, the bacilli

are sparse or may not be evident at all.76,78'86"87

The

earliest lesions seen in experimentally infected calves
are focal aggregates of macrophages in Peyer's patches
and in the villus tips.69"5^

Mast cell mediated

enteropathy of the cranial portions of the intestinal
tract is likely to be another feature in the early stages
of paratuberculosis.88
In regional lymph nodes there are multifocal

accumulations of macrophages and giant cells primarily
within the cortex.

These nodular accumulations

frequently coalesce.

Acid-fast bacilli are usually

demonstrable in these aggregates as well.
In the liver there may be multifocal granulomas and/or
pericholangitis.

Acid-fast bacilli are usually not

observed in hepatic lesions.7 8 '84
Intimal fibrosis and mineralization occur in the
abdominal aorta and heart8 8 '8 7 '89.

A fibrinoid or

amyloid-like substance may be present in small vessels of
lymph nodes, adrenals, udder, and renal glomeruli.44
Neurologic lesions such as degenerative changes in
the sciatic nerves and brachial plexus resembling
lepromatous leprosy have been reported.89

Acid-fast

bacilli are also present in these lesions.

Diagnosis
The antemortem diagnosis of paratuberculosis is
hindered by the absence of sensitive tests.

It should be

kept in mind that immunologic methods give an indication
of exposure and not infection and to distinguish between
resistant and infected animals may be impossible using
immunologic methods.
been employed.

Numerous diagnostic methods have

These include intradermal and

intraveneous johnin tests, complement fixation,
hemagglutination, agar gel immunodiffusion, enzyme-linked

immunosorbent assay (ELISA), radioimmunoassay,
fluorescent antibody, lymphocyte transformation,
migration inhibition, leukocyte migration,
immunoperoxidase, mucosal and lymph node biopsy, and
fecal culture.44

None of these tests have proven to be

completely accurate, providing variable percentages of
false negatives and false positives.

The available

number of confirmed ELISA test results is too small to
establish the accuracy of the test, but initial results
are promising.90

It has been speculated that false

positives only occur as the result of cross-reactivity
with other mycobacteria and that such spurious results
would be eliminated if pure and species specific antigens
are utilized.44

This does not appear to be true because

some animals develop a protective immunologic response,
eliminate the organism, and become positive by serologic
testing.44

These animals are then resistant to

reinfection but continue to be serologically positive and
should therefore not be culled, but be retained as
breeding stock.
False negative results occur due to anergy9^ or to
antigen masking factors.92"95

The failure to respond to

antigen usually occurs at the terminal stages of the
disease, but anergy may occur at any time during chronic
infection.44

In general, cell mediated immune responses

are susceptible to tolerance.96

An animal which is

immunologically tolerant may react humorally but fails to
develop an adequate cell mediated response.

An initial

serologically positive response with a subsequently
negative cellular response may be interpreted as anergy
in the infected state or following recovery from a
previous infection.
Serologic testing on an individual animal basis is
of little value.

Most infected herds, however, have a

prevalance of infection of 36%- 4 2 % . ^

Therefore, testing

10 out of 100 animals in an infected herd will result in
a 98% probability for finding a positive response.
Although probably the most variable in its results
and interpretation, intradermal johnin testing provides
an easy and convenient method of diagnosis which can be
used on the farm.®®

The test is performed similar to

tuberculin testing, except that results are read in 24-48
hours in cattle.

A change in skin thickness greater than

5 mm is considered a positive test.

Repeated tests can

be performed at any time, but different sites must be
used; apparently a local desensitization occurs at the
site of injection.44,97,98
Intraveneous johnin tests provide greater accuracy
than intrdermal testing, but requires 2-4 ml of
QQ

antigen. *

A positive reaction is indicated by a febrile

response or a change in the neutrophil:lymphocyte
r a t i o . A

rise in rectal temperature of 1.5°C within

six hours post-injection is considered a positive
response.

A shift in the neutrophil:lymphocyte ratio

greater than 2:1 at six hours post-injection is also
considered a positive test result.

Microbiology
The only means by which a definitive etiologic
diagnosis can be made is by cultivation of the organism
either from feces or infected tissues.

The organism is

usually grown on Herrold's egg yolk media and
identification is based on mycobactin dependence.®2

The

suspected material should be innoculated on two slants,
one with and one without mycobactin.

Mycobactin P and

mycobactin J will both support growth, however culture
times are reduced from 8 weeks to 4-6 weeks by using
mycobactin J.101

Mycobactin J is derived from

Mycobacterium paratuberculosis Ames Strain 18 and
enhances growth of strains which could otherwise not be
cultured.101,102

Fecal cultures further complicate the

isolation problem because of the necessity of
decontamination.

The feces (and contaminated tissue) are

suspended in benzalkonium chloride to destroy saprophytic
mycobacteria, fungi, and other bacterial contaminants
prior to inoculation onto appropriate media.101,104
Hexadecylpyridinium chloride at a concentration of 0.75%
has also been used and may prove to be a more effective

decontaminant than benzalkonium chloride.105

Even with

these decontaminating procedures, saprophytic overgrowth
frequently occurs.

Some isolates of Mycobacterium

paratuberculosis are highly sensitive to the
decontamination solutions.44

The minimum number of

organisms shed in the feces which can be detected by
fecal culture appears to be about 100 per gram of
feces,

however methods are available which can detect

1 organism/gram of feces.®8

Vaccination and Treatment
Vaccines have been used in attempts to control the
disease.

A number of bacterins, both attenuated and

unattenuated have been evaluated,118“121

In addition,

heat-killed organisms,122-124 and disrupted fragments of
Mycobacterium paratuberculosis117/124,125 have been used.
The effectiveness of these vaccines has been disputed.
However, the consensus is that vaccination will reduce
the number of clinical cases, decrease the number of
animals excreting the organism, and decrease the number
of animals with detectable intestinal
lesions.121/124/157/158

Vaccination does not confer

absolute immunity as some vaccinates may develop disease
or shed the organism.118/128/122-127
The main disadvantage to vaccination is that cattle

vaccinated with Mycobacterium paratuberculosis-origin
bacterins develop hypersensitivity to johnin, avian PPD,
tuberculin, and IXL_ bovis PPD.-*-2^

The vaccine is usually

administered at 1-35 days of age and immunity lasts about
18 months.12^-126

Revaccination is not recommended

because of the possibility of decreased resistance
following r e v a c c i n a t i o n . #121,128
The paratuberculosis organism is susceptible to
numerous antituberculous drugs in vitro, however
treatments have not been successful.107-115

jn these

attempts, animals frequently improve clinically, however
continue to shed the organism and some animals eventually
succumbed to the disease.

Immunoreactive Substances of Mycobacteria
The various species of mycobacteria have numerous
similar chemical and adjuvant properties.

All contain

various mycosides, trehalose dimycolate, murmayl
dipeptide, phosphotides, sulfatides, Waxes D, and water
soluble adjuvants which make them unique from a
immunological aspect.

The most common factor in the

mycobacterial component of Freund's complete adjuvant
having immunoadjuvant activity is known to be N-acylmuramyl-L-alanyl-D-isoglutamine, otherwise known as
muramyl dipeptide or MDP.

1 9Q

The multiplicity of MDP

effects have been outlined by Masek.

1 *30

A pyrogenicity

effect of MDP was noted soon after its discovery.
Somnogenicity, antinociceptivity, immunoadjuvanticity,
anti-inflammatory, and hepatoprotective effects have been
-ion
also described.
The target cell of MDP appears to be
-lOI

the macrophage. J±

Lymphocyte proliferative responses

seem to be secondary to the need for macrophages for Tcell activation.132“134,223,224
Another important adjuvant of mycobacterial origin
is trehalose dimycolate or cord factor.135

The name

’’cord factor" came from the observation that M.
tuberculosis in culture formed serpentine cords in
parallel arrangements.13®

Cord factor also has the
1 *37

ability to activate m a c r o p h a g e s ^ ' and cause secretion of
mitogenic factors by mouse thymocytes in conjunction with
addition of muramyl dipeptide.

1 Rfi
0

Cord factor is

granulomagenic, probably by virtue of its
chemotactic

IRQ

1 JO

#

■

1 R7

1RR

and stlmulant■L','' -LJO properties for

macrophages and has antitumor properties.141
The mycosides are a diverse group of glycolipids
which have become essential in serotyping organisms in
the Mycobacterium avium-intercellulare-scrofulaceum
complex.

The mycosides of bovine origin are designated

as mycoside B and are glycosylated phenolic phthicerol
esters.143

Studies by Brennan and colleagues,143-145

demonstrated that the glycosylated mycosides confer

antigenic and serologic specificity through an extremely
small oligosaccharide.

The same oligosaccharide has been

identified from prototype strains of Mycobacterium
paratuberculosis supplied by the National Disease Center
in Ames, Iowa.-^^

The compound is also identical to a

previously isolated oligosaccharide from a strain of Mj_
910

91

avium^1J •

A

and it has been suggested that M.

paratuberculosis may in fact be a specific ]yL_ avium
91 o

serotype. ■LJ

Additional studies by McFadden and others

have shown that M^_ avium and

paratuberculosis can be

distinguished on the bases of differences in their
restriction fragment length polymorphisms.215

Recently

lipoarabinomannan and lipid free arabinomannans have been
shown to be potent immunoreactive substances of
mycobacteria and in particular Mycobacterium
paratuberculosis, and these antigens have been used with
considerable success in enzyme immunoassays for Johne's
disease.218

Immunology of Paratuberculosis
There is a paucity of information on the cellular
immunology of Johne's disease compared to tuberculosis or
leprosy.

The clinical signs in cattle affected with

J o hne's disease have been postulated to result from an
allergic response to products of the o r g a n i s m . I t

is

speculated that an antigen-antibody reaction in the
infected tissue may cause the release of significant
amounts of histamine resulting in diarrhea.62

The

reaction of antigen with competent lymphocytes would then
cause the release of nonspecific pyrogen and cytotoxins
resulting in a febrile response, anemia, and emaciation.
With these speculations in mind, Merkal and Witzel used
whole blood, white blood cells, plasma, and febrile
plasma to passively transfer johnin hypersensitivity to
noninfected calves.146

All blood elements except for

non-febrile plasma were able to confer johnin
hypersensitivity with temporary fever and diarrhea.
Plasma factors which suppress in vitro lymphocyte
transformation have been identified in lepromatous
leprosy and paratuberculosis.
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in addition, in

lepromatous leprosy there is an extensive replacement of
paracortical areas in regional lymph nodes by
histiocytes.149
Johne's disease.

A similar replacement also occurs in
Therefore, it appears that the

destruction of paracortical areas in lymph nodes may
result in the inability to mount an effective immune
response.
Crohn's disease is a chronic inflammatory condition
of the intestinal tract which affects humans.
Histologically, the intestinal lesions are composed of a
diffuse, intense accumulation of macrophages in the

lamina propria and submucosa, not unlike bovine
paratuberculosis.

For years, the cause of Crohn's

disease has been unknown, however recently a
mycobacterium has been isolated from several clinical
cases.216

The mycobacterial agent has been identified as

M. paratuberculosis.216•21^ and through the use of DNA
probes has been shown to be indistinguishable from the
Johne's bacillus.216
Cattle affected with Johne's disease should provide
an excellent model for the study of the pathogenesis of
chronic intracellular infections.

Due to the

similarities of the various mycobacterial organisms and
the similarities in disease conditions, particularly
lepromatous leprosy, Crohn's disease and Johne's disease,
it can be postulated that there may also be similarities
in the cellular immunology.

Cellular Immunologic Events in Mycobacterial Infections
Although cellular immunity has only been
superficially examined in Johne's disease, it has been
closely examined in other mycobacterial diseases.

It

remains to be shown whether many of the observations
noted in other mycobacterial diseases may also apply to
Mycobacterium paratuberculosis infections.
Initial cellular events following the introduction of
mycobacterial antigen involve presentation of antigen to
appropriate lymphocytes.

Accessory cells such as

resident macrophages, dendritic cells, Langerhans cells
and M cells provide this function.

Resident macrophages

may not be as important as other non-lymphoid accessory
cells.150-152

jf major histocompatibility class (MHC) II

antigens (la antigen) are expressed on both the
accessory cells and T-lymphocytes, the foreign antigen
can be adequately presented and invoke the release of
soluble mediators such as interleukin 2 (IL-2) and gamma
interferon.

IL-2 is secreted by T-cells of the helper

cell phenotype.153,154

Normally IL-2 secretion can be

invoked by various plant lectins such as
phytohemagglutinin, conconavalin A, or pokeweed mitogen
and numerous antigens.

Calcium ionophore A 23187 in the

presence of phorbol myristate acetate has also recently
been shown to be a potent inducer of IL-2 synthesis.
The IL-2 invokes increased IL-2 receptor expression and

proliferation of a suitable clone of T-lymphocytes
(helpers, cytotoxic, and natural killers).156/157
IL-2 also regulates and augments interferon production-1-3®
which in turn is necessary for increased la antigen
expression.33® '^®®

Without la antigen expression,

accessory cell and lymphocyte interaction do not occur.
In certain mycobacterial infections there is a decrease
in macrophage la expression.163

Inhibition of IL-2 by

muramyl dipeptide, a constituent of mycobacterial
organisms, has been demonstrated.^®^

A decrease in

IL-2 production may explain the paucity of lymphocytes in
histologic lesions of chronic Johne's disease.
Mycobacterium infected macrophages have also been shown
to have decreased Fc receptor expression.-1-®3
It has been shown that lymphocytes incubated in
vitro with mycobacterial antigens produce a population
of lymphocytes that suppresses IL-2 production in normal
lymphocytes.

These antigens do not affect IL-1

production by normal monocytes.^®3

Macrophage Function
The role and function of the macrophage in
mycobacterial infections is controversial.

Various

research groups have obtained conflicting results. Much
of this conflict may be due to the fact that most studies
are performed on blood-derived macrophages or monocytes

instead of those mononuclear phagocytes actively
participating in the local lesions.
Macrophages infected with mycobacteria have a
decreased ability to kill other bacteria and phagocytize
zymosan.164,165,226

In addition, it has been shown that

phagosome-lysosome fusion is inhibited in mycobacteriuminfected macrophages when intact organisms such as
Bacillus subtilis and Mycobacterium avium are presented
to the affected macrophage.188
There may be a decrease in oxidant metabolite
production.

In addition to being cytocidal to

microorganisms, the oxidants produced by phagocytic cells
are necessary for production of carbonyl radicals on the
surface of lymphocytes which is a necessary prerequisite
for the production of IL-2.187

Infected

macrophages are

also known to inhibit lymphocyte blastogenesis and
lymphokine production.168

This activation may be

inhibited by calcium channel blockers and calmodulin
antagonists (i.e. acepromazine).169
Macrophages are responsible for IL-1 production
which in turn stimulates T-cells to express receptors and
secrete IL-2.170"178

In patients with lepromatous

leprosy there is an increase in prostaglandin-E2 which is
a potent inhibitor of IL-1 production^1 9 .

This can be

demonstrated in vitro with M^ leprae stimulated
macrophages from lepromatous individuals.174

Drutz et al has shown that leukocytes (monocytes,
macrophages, and polymorphonuclear cells) from
lepromatous and tuberculoid leprosy patients possess
equivalent microbiocidal activity towards Listeria
monocytogenes, E.coli, Proteus vulgaris, S. aureus, and
Candida albicans.175

In addition, Ridel has shown that

there is no difference in IL-1 production in lepromatous
patients compared to healthy individuals.174

In Crohn's

disease there appears to to an increase in IL-1
production

when induced and as a spontaneous

phenomenon. ^

This implies a state of chronic

activation or an inherent macrophage defect.
It has been documented that gamma-interferon is an
important activator of macrophages.17®-17^

Nogueira

demonstrated that peripheral blood lymphocytes of leprosy
patients fail to produce interferon and that production
was restored with the addition of purified IL-2.

1 ftO

Kaplan reported that macrophages from lepromatous
leprosy patients were deficient in hydrogen peroxide
production, but responded similarly to those from healthy
individuals after the addition of interferon and that
this effect was independent of prior macrophage ingestion
of M.leprae bacilli.181

This study concluded that the

immune defect was a lack of response to

leprae by the

patients' T-cells rather than a defective response of
macrophages to interferon.

It has been shown in patients with lepromatous
leprosy that there was no increase in C-reactive
protein183.

It is known that IL-1 is responsible for C-

reactive protein production in acute phase inflammatory
responses.183,184

Together these findings suggested that

IL-1 production may also be decreased in mycobacterial
infections.
Macrophage lysates from lepromatous leprosy patients
have been shown to produce non-dialyzable antigen
specific suppressor factors.185,186

Proliferation of T-

lymphocytes and macrophages promoted by conconavilin A
and other mycobacteria were inhibited by these lysates.
Natural killer cells were essential in tumor
surveillance and and destruction of parasitized
cells (macrophages).18^ f188

Cytotoxic T-cells performed

roughly the same function, however natural killer cells
did not require MHC matching with target cells.

In some

mycobacterial infections, IL-2, which is important in
killer cell proliferation, has been demonstrated to be
deficient.189
In patients with lepromatous leprosy a decrease in
the T4/T8 ratio in the lesions indicated a relative
decrease in helper cell activity, therefore the cells
necessary for IL-2 production were deficient in
number.190

In addition, studies using anti-Tac antibody

labeling have shown that there was a decrease in IL-2

receptor expression, but lymphocyte function could not be
fully restored with the addition of exogenous IL-2
alone191.

Immunomodulation
Dialyzable leukocyte extracts containing transfer
factor augmented cellular and humoral immunity.193
Transfer factor has been considered a portion
of or the entire cell receptor for IL-2.

Leprosy

patients or paratuberculosis infected animals should
benefit greatly from treatment with transfer factor.
Supplementation with IL-2 may increase the immune
response by reinstituting cellular proliferation of Thelper cells in those mycobacterial diseases in which IL2 is deficient. Pharmacologic enhancement of macrophage
function may lead to enhanced IL-1 production.

This in

turn may result in increased IL-2 receptor expression on
lymphocytes193 and augmented proliferative and functional
responses.
Since the discovery of transfer factor by
Lawerence,19^ '193 viable leukocytes, leukocyte extracts,
or dialysates of leukocyte extracts have been used to
transfer delayed hypersensitivity to previously naive
individuals.

Clinical syndromes treated with transfer

factor have included cancer immunotherapy,196-198
internal parasitism,199 lupus erythematosus,366

sarcoidosis,

901

vaccinia,

909

coccidiomycosis,20^ tuberculosis,20^ lepromatous
leprosy205* and numerous others.

The results have been

variable, but were often favorable.
Leukocyte lysates which contained inducer factors
(transfer factor) and supressor factors have been
obtained from T-helper and T-suppressor cells,
respectively.206

Much of the variability noted in

clinical applications

probably has been due to the fact

that the crude lysates contained mixtures of both
factors.207-210

The suppressor factor has also been used

in the modulation of diseases such as lupus
erythematosis200 and autoimmune thrombocytopenic
purpura211 that are characterized by an undesirable
immune response.

Certain chemical and biological

properties of transfer factor have been well
documented206.

In dialysates, the active component was

present in the 3.5 to 12kD molecular weight range.
Transfer factor binds to specific antigen and anti-la
antibody.

The product was absorbed by T-suppressor cells

and macrophages.

In addition, transfer factor equipped

nonimmune cells with an antigen-binding moiety.206
has been postulated that transfer factor may be a
dialyzable fragment of a T-helper cell receptor206
(possibly IL-2 receptor).

The duration of effect of

treatment with transfer factor has not been well

It

documented in every case.

In a study using transfer

factor as a preventative measure against varicella-zoster
exposure, it was found that titers of treated, exposed
patients who were protected from disease developed
antibody titers that remained as high as those in
infected individuals for 17 months.2^-2

The transfer

factor treated group also had an active cell mediated
immunity as demonstrated by in vitro and skin tests for
the same period of time.
In a study using transfer factor in
lepromatous leprosy, donors for transfer factor were
selected on the basis of positive skin reactivity and in
vitro lymphocyte responses.205

Recipients were initially

negative to skin tests using lepromin.

After

administration of transfer factor the recipients became
skin test positive after the first or third days.

In

vitro testing of lymphocyte function (blastogenesis) was
not altered.

The recipients experienced erythema of the

cutaneous lesions and occasionally fever.

There was no

alteration in histologic characteristics of the lesions
when compared to pre-transfer factor lesions.

The

majority of the recipients reverted to a skin test
negative status about 25 months after transfer factor
administration.

These changes, although shortlived were

extremely promising when it is considered that only one
injection of transfer factor was given.205

A multiple

dose trial appears indicated.

Chemotherapy
As previously stated, several anti-tuberculous drugs
have been used to treat Johne's disease with little or no
success.

Clofazimine and isoniazid have been used most

extensively although in a limited number of animals. 109
A relatively new compound, Rifabutin (ansamycin LM 427),
appeared promising.22*

Preliminary results with

rifabutin therapy in stump-tailed Macaques infected with
M. paratuberculosis demonstrated remission of clinical
signs and an extended life expectancy.219

Objectives
The exact nature of the immune defect in
mycobacterial infections has not been determined
Lymphocyte-macrophage interactions are extremely complex
and difficult to dissect from one another.

Transfer

factor appears to augment lymphocyte function and not
affect other aspects of cellular immunity.

There are

pharmacologic agents and other chemicals which augment
monocyte/macrophage function with little or no effect on
lymphocyte function.

Proper macrophage function should

also be restored if the infectious agent or antigen can
be removed by an effective antimicrobial agent.

The objectives of this study were:
1.

To determine the existence and nature of the cellular

immune defect in cattle naturally infected with
Mycobacterium paratuberculosis.

Specific objectives

included:
(a) Skin hypersensitivity to johnin, M^ bovis PPD,
and keyhole limpet hemocyanin antigens.
(b) Lymphocyte blastogenic responses, macrophage
migration inhibition factor production, interleukin-1
release and interleukin-2 production in response to the
skin test antigens.

2.

To determine the response of cattle with chronic

paratuberculosis and non-infected cattle inoculated with
Mycobacterium paratuberculosis bacterin, live M^_ bovis
BCG, and keyhole limpet hemocyanin in Freund's incomplete
adjuvant to the specific parameters outlined in objective
1.

3.

To determine the cell-mediated immune response in

three naturally infected cattle with paratuberculosis
using the assays outlined in objective 1 following
weekly treatment for three weeks with specific transfer
factor prepared to keyhole limpet hemocyanin and
Mycobacterium paratuberculosis.

4.

To determine the cell-mediated immune response in

three naturally infected cattle with paratuberculosis
using the assays outlined in objective 1 after daily
treatment with 1200 mg rifabutin for three weeks.

5.

To determine the extent of lesion alterations in

ileal and ileocecal lymph nodes in the cattle described
in objectives 3 and 4 before and after transfer factor
and rifabutin treatment.

CHAPTER 2

LYMPHOCYTE BLASTOGENESIS AND MACROPHAGE MIGRATION
INHIBITION IN CATTLE WITH CHRONIC BOVINE PARATUBERCULOSIS
BEFORE AND AFTER SENSITIZATION WITH ML PARATUBERCULOSIS,
M;. BOVIS AND KEYHOLE LIMPET HEMOCYANIN

Abstract
Cutaneous hypersensitivity, lymphocyte blastogenesis
and macrophage migration inhibition in response to M.
bovis PPD, johnin, keyhole limpet hemocyanin, and
phytohemaglutinin were examined in 3 cattle naturally
infected with Mycobacterium paratuberculosis and 3 non
infected cattle.

Infected cattle had variable response

to the skin test antigens and largest blastogenic
responses to Mj. bovis PPD also with positive responses
to johnin.

No significant blastogenic responses were

seen with keyhole limpet hemocyanin in either group.
Blastogenic responses with phytohemaglutinin were similar
in both groups.

The results of macrophage migration

inhibition paralleled the lymphocyte blastogenic
responses to the antigens and mitogen.
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Sensitization
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with

bovis BCG, ML_ paratuberculosis, and keyhole

limpet hemocyanin in Freund's incomplete adjuvant
resulted in positive skin tests, blastogenic and
migration inhibition responses in control cattle with M.
bovis PPD, johnin, and keyhole
limpet hemocyanin and no change in the phytohemaglutinin
responses.

There was no difference in pre- and post

sensitization blastogenesis and inhibition of migration
data in infected cattle.

There was, however, a

significant decrease in johnin and M^ bovis PPD skin test
reactivity and a failure to produce positive responses to
keyhole limpet hemocyanin and Mj_ bovis PPD after
sensitization.

Introduction
Bovine paratuberculosis is a chronic enteric
infection caused by Mycobacterium paratuberculosis which
results in diarrhea, weight loss and eventually death.8
Numerous serologic tests for the antemortem diagnosis of
paratuberculosis have been used with inconsistent
results.

Q

Lymphocyte blastogenesis (LB) and macrophage

migration inhibition factor (MIF) assays have been
suggested as good in vitro indicators of the cell
mediated immune response.11*15,18

These assays have

also been used for the diagnosis of paratuberculosis.*'87,10,13,14,16

Anergy is known to occur in bovine paratuberculosis.

o

Whether this anergy is complete or specific for only M.
paratuberculosis has not been well characterized.

In the

this study, cell mediated immune responsiveness was was
measured by skin testing and LB and MIF assays in cattle
with chronic paratuberculosis before and after
administration of sensitizing doses of M^ bovis BCG, M.
paratuberculosis. and keyhole limpet hemocyanin (K L H ).
This was done to determine whether or not cattle infected
with M^ paratuberculosis can distinguish between and
mount a positive immune response to homologous and
heterologous antigens as assessed by LB, MIF, and skin
testing.
Materials and Methods
Animals:
Three adult Brahman-cross cattle diagnosed positive
for bovine paratuberculosis by rectal biopsy, ileal
biopsy and by enzyme-linked immunosorbent assay.19

were

donated to the Louisiana State University School of
Veterinary Medicine by local cattle producers.

These

animals had a history of weight loss and intermittent
diarrhea of at least one year, duration.

In addition, 3

healthy control cattle were selected at random from the
School of Veterinary Medicine teaching herd to serve as
controls.

Fecal cultures from control animals using

Herrold's egg-yolk media with and without 2 ug/ml

mycobactin J (Allied Labs, Ames,IA) were negative after 6
months of incubation.

Media and Reagents
The culture medium used for the LB assays consisted
of RPMI 1640 (GIBCO Laboratories, Chargin Falls, OH)
supplemented with 4 mM L-glutamine and 10% fetal calf
serum (FCS) without antibiotics (complete culture medium,
COM).

Dulbecco's MEM (GIBCO Laboratories, Chargin Falls,

OH) was used in the MIF assay.

Phosphate-buffered saline

(PBS) was used as a washing solution.

Phytohemaglutinin

(PHA), keyhole limpet hemocyanin (KLH) (Sigma Chemical
Co., St. Louis, MO), johnin and Mycobacterium bovis (M.
bovis) PPD (Veterinary Services Laboratory, Ames, IA)
were diluted to appropriate concentrations (as determined
by previous dose response trials) in CCM.

Mycobacterium

bovis (Trudeau Institute, Saranac Lake, NY),
Mycobacterium paratuberculosis bacterin (Fromm
Laboratories, Grafton, W I ), and KLH in Freund's
incomplete adjuvant (Sigma Chemical Co. St. Louis, MO)
were used to sensitize both groups.

Freshly prepared

[3H ]thymidine in CCM was used to assess proliferative
responses in blastogenesis assays.

Skin Testing
The cervical area of each cow was clipped and double

skin thickness measured prior to injection.

Intradermal

injections of 0.2 ml containing .1000 p.g johnin, M^ bovis
PPD and KLH in PBS were given to each cow.
negative control PBS was used.

For a

The change in double skin

thickness was recorded after 48 hrs.

The cattle were

retested using the contralateral cervical area after
sensitization.

A change in skin thickness >5mm was

considered a positive reaction.

Blood Mononuclear Cells
Heparinized whole blood was collected by venapuncture
and diluted 1:1 with PBS.

An equal volume of Histopaque-

1.083 (Sigma Chemical Co., St. Louis, MO) was slowly
injected underneath the blood using a 6 in, 18 ga needle.
The blood-Histopaque gradient was centrifuged at 1000 X g
for 45 min and the mononuclear cell band at the interface
was removed and the cells washed three times with PBS.
Platelet contamination was minimized by differential lowspeed centrifugation during washing (250 X g for 10 min).
Viability by trypan blue exclusion was >95%.

Lymphocyte Blastogenesis
Gradient-separated mononuclear cells were suspended
in CCM at a concentration of 2 X 106/ml and 100 ul
aliquots were placed in the wells of a 96 well
microtiter plate.

To triplicate wells was added 100 ul

of one of the following in CCM: 50 ug/ml johnin, 50 ug/ml
M. bovis PPD, 30 ug/ml KLH, 25 ug/ml PHA, and CCM without
additive.

The cells were incubated for 72 hrs., pulsed

with 0.5 uCi/50ul [3H ]thymidine, and collected 18 hrs
later onto glass fiber disks using a semi-automated cell
harvester (Skantron Inc., Sterling, V A ) .

The disks were

dried overnight at 60°C and placed in scintillation vials
to which was added 3 ml of scintillation cocktail
(Fluoralloy™ in toluene, Beckman Instruments, Fullerton,
CA).

The vials were placed in the dark overnight to

minimize inherent chemiluminescence.

Counts were made

for 2 min on a Packard Tri-Carb 4640 beta counter
(Packard Instrument Co., Downers Grove, IL).

The data

was expressed as the antigen cpm/media cpm stimulation
index (S I ).

A SI > 2.0 was assigned as a positive

response as previously determined.

Migration Inhibition Factor Assay
A microagarose droplet assay as described by
Harrington and Stastny was used with minor
modifications.

Cell pellets containing 10® gradient-

separated mononuclear cells were combined with 100 ul of
2 X Dulbecco's MEM with 20% FCS and 100 ul melted agarose
(SeaPlaque™, FMC Corporation, Rockland, ME).

The cells,

media and agarose were gently mixed and 1 ul droplets
were placed in the center of the wells of a 96 flatbottom

well microtiter plate.
for 10 min prior to

The plate was refrigerated (4°C)

the addition of antigens.

To

triplicate wells 100 jil CCM was added containg one of
following: 50 yg/ml

johnin, 50 ug/ml ML_ bovis PPD, 50

p.g/ml KLH, 25 \ig/ml

PHA and CCM without additive.

the

After

48 hrs incubation each well was photographed and a 5 X 7
was print made.

The two most symmetrical droplets from

each treatment were selected and the distance from the
edge of the droplet to the edge of the cell migration
zone was measured.

Three random measurements were made

from each of the selected droplets and the mean and
standard error was calculated.
inhibition of migration:

Data were expressed as %

[(mean migration distance of

media control) -(mean migration distance of
antigen)/(mean migration distance of media control)] X
100.

A 20% inhibition was considered a positive MIF

assay reaction.'

Sensitization
Infected and non-infected cattle were inoculated
subcutaneously with 8.0 mg KLH in Freund's incomplete
adjuvant, 1.0 ml heat-killed

paratuberculosis bacterin

(twice the recommended dose), and 6 X 10® MN_ bovis BCG.
All assays were repeated 3 weeks after the sensitizing
injections.

Statistics
Differences in stimulation indices and % inhibition
of migration in both the infected and non-infected groups
were tested using Student's t-test.

A significant

difference was considered to be P<0.05.
Results
Before sensitization two of three infected cattle had
a positive skin test reaction to johnin (table 1).
Slight increases were seen with M.bovis PPD before
sensitization and no significant changes were seen with
KLH or the CCM control.

No positive skin test reactions

were seen in the non-infected group before sensitization
(table 2).

After sensitization the non-infected cattle

had positive skin test responses to M^_ bovis PPD, johnin,
and KLH (table 2) while infected cattle had no positive
skin test reactions to any of the antigens used (table

1 ).
The LB assay was positive in all the infected animals
before sensitization with johnin and M^ bovis PPD (table
3).

No positive responses were seen with KLH in either

group.

No significant (P>0.05) difference in PHA induced

proliferation was seen in either group.

After

sensitization infected cattle showed no change whereas
control cattle significantly (P<0.05) increased LB
responses to all the sensitizing antigens (table 4).

No

difference (P>0.05) in the PHA response was detected.
The results of the MIF (tables 5 and 6) assay
paralleled the LB assay.

Infecetd cattle had positive

responses with IL bovis PPD and johnin before
sensitization with no change after sensitization.
Control cattle significantly (P<0.05) increased responses
to the sensitizing antigens.

Stimulation with PHA

consistantly produced a % inhibition of migration >98% in
both groups of cattle.

Discussion
The LB and MIF assays used in this experiment were
accurate indicators of chronic paratuberculosis.

Skin

testing with johnin and M^_ bovis PPD were not reliable as
previously indicated.8

After administration of

sensitizing doses of M^_ bovis BCG, M^_ paratuberculosis,
and KLH the control cattle developed positive skin tests,
LB, and MIF assay reactions which were significantly
different than pre-sensitization results. There was no
change after sensitization in LB and MIF assays in the
infected group, however there was a significant decrease
in johnin skin test reactivity.

It has been been shown

that infected cattle can be desensitized with
administration of johnin.8

This may account for the

decrease in skin reactivity with johnin, but does not
account for the failure to develop a positive skin

reaction to KLH and

bovis PPD after sensitization.

The phenomenon of positive LB with concurrent negative
skin test reactions as seen in this experiment has also
been previously reported.10
The majority of previous studies using lymphocyte
blastogenesis assays employed the whole blood
technique.6,6,10,13

These studies revealed a significant

number of false positives and negatives with marked
individual variation.

This has been attributed to serum

factors in cattle with paratuberculosis which inhibit
lymphocyte proliferation.9

Using a purified blood

mononuclear cell assay improved the specificity of the
technique markedly.2,16

In addition, heavily infected

cattle have greater variation in LB than minimally
infected cattle.10

Mycobacterial antigens other than

johnin have been used in blastogenesis assays with
varying results.

In general Mycobacterium avium antigen

provided equal or greater proliferative responses in
infected animals6,13,16.

It has been suggested that the

LB assay can distinguish between KL_ paratuberculosis and
M. bovis and that M^ avium infections can be
differentiated from M^ bovis infections.2,16,17 The
results of this experiment indicate that ML_ bovis PPD is
a better test antigen in the detection of infected
animals than johnin, and that this would make it
impossible to distinguish between paratuberculosis and M^_

bovis infections.

The differences noted in these two

mycobacterial antigens may be a reflection of different
potencies of the preparations as the same absolute
quantities were used.
In this experiment the LB and MIF assays have been
demonstrated to be accurate immunologic tests for the
antemortem diagnosis of bovine paratuberculosis.

The

unreliability of skin testing as a diagnostic tool has
been further substantiated.

Infected cattle fail to

produce a positive cellular immune response to
heterologous antigen at a dose shown to sensitize noninfected cattle.
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Table 1.

Delayed Cutaneous Hypersensitivity

in Mycobacterium partuberculosis Infected Cattle

Pre-Sensitization

Post-Sensitizati<

Change in Skin

Change in Skin

Thickness (mm)

Antigen

Cattle
#1
#2

#3

Thickness (mm)

#1

Cattle
#2

#3

PBSa

0.0

0.1

0.1

0.3

0.0

0.0

PPDb

2.3

3.8

3.6

2.2

1.9

3.0

johnin

3.5

11.1

9.8

2.7

2.1

3.2

KLHC

0.0

0.4

0.2

0.2

0.2

0.6

mean+SD

mean+SD

PBS

0.07+0.06

0.01+0.17

PPD

3.23+0.81

2.37+0.57

johnin

8.13+4.06*

2.67+0.55

KLH

0.20+0.20

0.33+0.23

aPhosphate buffered saline.
^Derived from M^ bovis.
cKeyhole limpet hemocyanin.
•ff

Positive rection (>5mm increase).
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Table 2.

Delayed Cutaneous Hypersensitivity
in Healthy Control Cattle

Pre-Sensitization

Post-Sensitization

Change in Skin

Change in Skin

Thickness (mm)

Antigen

#1

Cattle
#2

#3

Thickness (mm)

#1

Cattle
#2

#3

PBSa

0.2

0.1

0.0

0.4

0.1

0.0

PPDb

1.6

0.9

0.4

18.5

27.5

23.2

johnin

1.7

2.0

0.9

11.9

15.2

14.5

KLHC

0.0

0.2

0.3

6.3

9.7

11.4

mean+SD

mean+SD

PBS

0.10+0.10

0.17+0.21

PPD

0.97+0.60

23.07+4.50*

johnin

1.53+0.56

13.86+1.74*

KLH

0.17+0.15

9.13+2.60*

aPhosphate buffered saline.
^Derived from

bovis.

cKeyhole limpet hemocyanin.
Significantly different than pre-sensitization (P<0.05).

Table 3.

Lymphocyte Blastogenesis

in Mycobacterium partuberculosis Infected Cattle

SIa

cpm

773

1.0

460

PPDb

8,039

10.1

4,278

9.7

johnin

5,101

7.0

2,346

00
•

KLHC

1,391

1.5

828

1.4

PHAd

17,624

23.8

11,316

24.2

cpm

SI
1

Antigen

Post-sensitization

•
o

Pre-sensitization

media

aThe mean SI was calculated by dividing the mean antigen
cpm of triplicate assays from each of the 3 infected
animals by the cpm of the media control.

SD did not

exceed 10% of the mean.
^Derived from IL bovis; ckeyhole limpet hemocyanin;
dphytohemaglutinin.
All antigen and mitogen responses are significantly
different than the media control (P<0.05).

No

differences are apparent between pre- and post
sensitization data.

Table 4.

Lymphocyte Blastogenesis
in Healthy Control Cattle

Pre-sensitization

Antigen

Post-sensitization

cpm

SIa

cpm

SI

media

1,113

1.0

976

1.0

PPDb

1,001

0.9

5,270

5. 9*e

890

0.9

4,587

5. 0*e

KLHC

1,447

1.5

3,806

3. 7*e

PHAd

22,371

johnin

20.8e

21,765

22.0e

aThe mean SI was calculated by dividing the mean antigen
cpm of triplicate assays from each of the 3 infected
animals by the cpm of the media control.

SD did not

exceed 10% of the mean.
^Derived from

bovis; ckeyhole limpet hemocyanin;

dphytohemaglutinin.
Significantly different than pre-sensitization data
(P<0.05).
eSignificantly different than media control (P<0.05).
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Table 5. Mean Percent Inhibition of Migration
in Mycobacterium paratuberculosis Infected Cattle

Antigen

Pre-Sensitization

Post-Sensitization

PPDb

76.2+ 8.5a

72.4+9.3

johnin

56.6+6.6

59.1+7.7

KLHC

19.5+1.2

15.3+7.0

aMean+SE
^Derived from jML_ bovis; ckeyhole limpet hemocyanin.
%inhibition of migration with phyohemalutinin exceeded
98% in all assays.
A positive response is >20% inhibition.
No significant difference after sessitization.
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Table 6. Mean Percent Inhibition of Migration
of Healthy Control Cattle

Antigen

Pre-Sensitization

Post-Sensitization

11.7+ 3.2a

37.0+ 5.1*

johnin

8.0+ 4.3

33.6+ 4.0*

KLHC

5.5+ 2.8

23.8+ 4.6*

PPDb

aMean+SE
^Derived from M^_ bovis; ckeyhole limpet hemocyanin.
Significantly different than pre-sensitization data
(PC0.05).
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CHAPTER 3

INTERLEUKIN-1 RELEASE BY BLOOD MONOCYTES FROM
CATTLE NATURALLY INFECTED WITH MYCOBACTERIUM
PARATUBERCULOSIS

Abstract
Interleukin-1 (IL-1) release from blood monocytes
was measured using a mouse thymocyte proliferation assay.
Levels were determined in 3 cattle naturally infected
with Mycobacterium paratuberculosis and 3 non-infected
cattle.

Release of IL-1 was measured before and after

sensitization with heat-killed Mycobacterium
paratuberculosis. live Mycobacterium bovis BCG, and
keyhole limpet hemocyanin.

Monocytes from infected

cattle before in vivo sensitization spontaneously
released high levels of IL-1 and increased IL-1 release
in response to bacterial lipopolysaccharide.

Non-

infected cattle had increased IL-1 release when blood
monocytes were stimulated with Mi. bovis PPD,
lipopolysaccharide, and johnin. Johnin produced the
greatest response.

Release of IL-1 after sensitization

was unaltered in both groups.

These data suggest either

a chronic state of activation in blood monocytes
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or a defective regulatory mechanism for IL-1 in cattle
infected with Mycobacterium paratuberculosis.

Introduction
Bovine paratuberculosis (Johne's disease) is a
chronic enteric infection caused by Mycobacterium
paratuberculosis most often affecting ruminants.*1

The

disease has a marked histopathologic resemblance to
lepromatous leprosy and Crohn's disease and has been
proposed as an animal model for Crohn's disease.28

Based

on the similarity of the enteric lesions, it may be
postulated that similar inflammatory and immunologic
mechanisms occur in these diseases.

Measurement of

cytokine release and function in bovine paratuberculosis
has been limited to the study of migration inhibition
factor2 and indirect evaluation with lymphocyte
blastogenic responses.6 /13 »14,19,21
Interleukin-1 (IL-1) produced by antigenic
stimulation of macrophages (M$) has many molecular forms
1 7

and functions.'1

Its relationship to a variety of

different disease conditions has also been examined.
Spontaneous release of IL-1 from blood monocytes, M$> or
alveolar M$ has been noted in patients with
sarcoidosis,20 tuberculoid leprosy,25 scleroderma,1
tuberculosis,9 and Crohn's disease.20

In lepromatous

leprosy blood monocyte-derived M$ fail to produce IL-1

initially, but can produce normal levels when
cycloxygenase inhibitors, such as indomethacin, are added
to the IL-1 producing blood c e l l s . T h i s

restoration

effect was seen only in response to Mycobacterium leprae.
In other disease conditions such as sarcoidosis,
tuberculosis, and Crohn's disease, IL-1 was examined
because of the central role of the M$ in the lesions of
these diseases.

In scleroderma, the principle lesion

component is an overabundance of collagen with the M$
having only a minor role in lesion formation.

However,

examination of the role of IL-1 in this disease is also
warranted because of its ability

to induce fibroblast

activation and proliferation,
The role of IL-1 in the pathogenesis of bovine
paratuberculosis and an evaluation of host immune status
has not been previously examined.

As the M$ is the main

cellular component in the lesions of paratuberculosis,
the ability of blood monocytes to produce and release IL1

in cattle with chronic paratuberculosis was measured.

Alterations in IL-1 release were also measured after
sensitization with Mycobacterium paratuberculosis (M.
paraTB), Mycobacterium bovis (M. bovis), and keyhole
limpet hemocyanin (KLH).

Materials and Methods

Animals:

Three adult Brahaman-cross cattle diagnosed positive
for Johne's disease by rectal biopsy, ileal biopsy and by
enzyme-linked immunosorbent assay as previously
described.39 were donated to the Louisiana State
University School of Veterinary Medicine by local cattle
producers.

These animals had a history of weight loss

and intermittant diarhea for at least one year.

Non-

infected animals were selected at random from the School
of Veterinary Medicine teaching herd to seve as controls.
Fecal cultures from control animals incubated on
Herrold's egg-yolk media with and without 2 ug/ml
mycobactin J (Allied Labs, Ames,IA) were negative after 6
months.

Media and Reagents:
Culture medium (RPMI 1640, GIBCO Laboratories,
Chargin Falls, Ohio) supplemented with 4mM L-glutamine
and 2% heat-inactivated fetal calf serum (FCS) without
antibiotics was used for cell cultures from which IL-1
supernatants were prepared.

Similar medium was used for

the IL-1 assay with the addition of 10% FCS.

Phosphate-

buffered saline (PBS), pH = 7.4, was used as a washing

solution.

Concanavalin A (Con A), KLH, Serratia

marscecens LPS (Sigma Chemical Co., St.Louis, MO), johnin
and

bovis PPD (Veterinary Services Laboratory, USDA,

Ames, IA), were diluted to the appropriate concentrations
(as determined by previous dose response trials) in media
with 2% FCS.

Infected and non-infected cattle were

inoculated subcutaneously with 8.0 mg KLH in Freund's
incomplete adjuvant (Sigma Chemical Co., St. Louis, MO),
0.5 ml heat-killed M^ paraTB in oil (Fromm Laboratories,
Grafton, W I ),

and 6 X 108 MU bovis BCG (Trudeau

Institue, Saranac Lake, NY).

In vivo sensitization was

evaluated by skin test reactivity, migration inhibition,
and blastogenic responses using the sensitizing antigens
(Chapter 2).

Preparation of Monocytes:
Blood (40 ml) was collected using 50 U/ml
preservative-free heparin (Sigma Chemical Co., St. Louis,
MO) as an anticoagulant.

After diluting the blood 1:1

with PBS and equal volume of HistopaqueR (1.083 g/ml,
Sigma Chemical, St. Louis, MO) was injected underneath
the diluted blood using a 6 in, 18 ga needle.

The blood-

HistopaqueR gradient was centrifuged at 1000 X g for 45
min and the peripheral blood mononuclear cell layer at
the interface was harvested.

Cells were washed three

times in PBS and suspended at a final concentration of 8
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X 10®/ml in media with 2% FCS.

Platelet contamination

was minimized by differential low speed centrifugation
during washing (250 X g for 10 m i n ) .

The cells were

incubated in a 75 cm2 plastic culture flask (15 to 20 ml
per flask) for 1 h.

Non-adherent cells were removed by

vigorously washing 5 times with PBS.

Adherent cells were

removed using a plastic cell scraper and suspended in
media containing 2% FCS at a concentration of 1 X 106/ml
(trypan blue exclusion showed a viability of >90%).
Recovered adherent cells consisted of >95% monocytes with
slight platelet contamination.

Aliquots of adherent

cells (1ml) were placed in wells of a 24 well flat bottom
plate (Corning Glass Works, Corning, NY).

Preparation of IL-1 Containing Supernatants:

To 1 ml of 1 X 10® adherent cells/ml from each
animal was added equal volumes of the following; media
with 2% FCS, 50 y.g/ml

johnin, 50 ug/ml

ug/ml KLH, and 20 y.g/ml LPS.
hrs at 37°C and 5% CO2 .

bovis PPD, 50

Cells were cultured for 24

Supernatants were collected and

maintained at -60°C until assayed (within 2 weeks).

IL-1 Assay:
The assay for IL-1 followed the guidelines as

reviewed by Gearing, et al

1^

with minor modifications.

Adherent cell supernatants were thawed and serial two
fold dilutions were made with media to 1:64.

The

thymuses from 6 wk old C3H/HeJ mice (Jackson
Laboratories, Bar Harbor, ME) were used in all assays.
Each thymus was aseptically removed and teased apart in 5
ml of media.

The thymocytes and thymic tissue were

allowed to sediment at 1 X g for ten minutes.

About 4 ml

of cell suspension was withdrawn and adjusted to a final
concentration of 5 X 106/ml in media containing 10% FCS
and 1.5 ug/ml Con A.
exclusion was >95%.

Viability assesed by trypan blue
100 p.1 aliqouts of thymocytes were

added to the wells of a 96 flatbottom well culture plate.
An equal volume of the varying dilutions of adherent cell
supernatants was added to the thymocyte cultures.

After

incubation for 48 hrs, 0.5 y.Ci/50y.l [ ] thymidine in RPMI
with 10% FCS was added to each well.

Cells were

harvested after 18 hr incubation onto glass fiber discs
using a semi-automated cell harvestor (Skraton Inc.,
Sterling, V A ) .

Glass fiber discs were dried overnight

at 60°C, placed in scintillation vials and 3 ml of
scintillation cocktail (Fluoralloy™, Beckman
Instruments, Fullerton, CA.) was added.

The samples were

placed in the dark overnight to minimize inherent
chemiluminescence before beta counting.

Counts were made

for two minutes on a Packard Tri-Carb 4640 beta counter

(Packard Instrument Co., Downers Grove, IL).

All assays

were performed in triplicate. Supernatants were initially
screened for interleukin-2 by means of a Con A-blast
proliferation assay.
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Statistical Analysis:

Wilcoxon's rank sum test was used to identify
treatment group differences in IL-1 release; a difference
was considered significant at P<0.05.

Results
The concentration of IL-2 in the monocyte-derived
supernatants was negligible by the Con A blast assay.
The results of the mouse thymocyte proliferation assay
before sensitization are shown in Table 1.
obtained from media, KLH,

Supernatants

bovis PPD, and LPS-

stimulated monocytes induced thymocyte proliferative
responses which were significantly (P<0.05) greater in
the infected group than in noninfected controls.
Proliferative responses produced by johnin stimulated
monocyte supernatants were not significantly (P>0.05)
lower in the infected group. The LPS-stimulated
supernatants produced significantly (P<0.05) greater
proliferative responses when compared to the media

control in both groups.

The control group monocyte

response was significantly (P<0.05) greater with johnin
antigen when compared to the other antigens, although all
treatments are significant (P<0.05) compared to responses
obtained with the media control.
proliferative responses with

The thymocyte
bovis BCG,

paraTB, and

KLH in the same groups of animals after sensitization is
presented in Table 2.

Although the cpm differed greatly

before and after sensitization, stimulation indices for
the IL-1 responses were remarkably similar.

There was a

significant (P<0.05) decrease in cpm values corresponding
to all stimuli in both groups of animals.

Stimulation

with johnin remained significantly (P<0.05) higher in the
non-infected group after sensitization.

The infected and

non infected groups had similar KLH and PPD responses.

Discussion
The lesions of bovine paratuberculosis typically
reveal a marked infiltration of

containing large

numbers of Mj_ paraTB organisms in the lamina propria and
submucosa of the small intestine and in the cortex and
medulla of mesenteric lymph nodes.

Disseminated disease

is rare, but has been reported^'*1 '1® and is felt to be
the result of terminal anergy.*-1- As the

is

the main lesion component and provides a major initial
defense mechanism against mycobacterial disease,

investigation in M$ function with respect to cytokine
production and/or release seems warranted.
It has been shown that bovine blood monocytes and
monocyte derived

readily phagocytose

fail to kill the organism.5 '3^

paraTB, but

In other mycobacterial

diseases, such as Mycobacterium leprae infections, M3>
react similarly in that there is a failure to kill the
organism or other phagocytosed organisms even when M.
leprae-burdened macrophages are exposed to exogenous
interferon gamma. ^
In this study the blood monocytes from
infected cattle spontaneously release IL-1.

paraTB
This

phenomenon has been seen in other granulomatous diseases
1

on

such as scleroderma ,* sarcoidosis, w tuberculoid
leprosy,35 and Crohn's disease.3®

The similarities

between bovine paratuberculosis and Crohn's disease
extend beyond lesion morphology and spontaneous IL-1
release by blood monocytes.

Recently a mycobacterial

agent has been isolated from several Crohn's
patients.

1 n *3^

Three separate isolates have been shown

to be indistinguishable from M^_ paraTB ATCC 19698 by
using DNA probes which distinguish between mycobacterial
species.26

The spontaneous release of IL-1 by alveolar

MS> in sarcoidosis may be partially accounted for by the
low levels of prostaglandin E2 (PGE2 ) produced by these
cells m

vitro.

Prostaglandin-E2 is a known

autoregulatory monokine of IL-1 production.1 5 '24

In

lepromatous leprosy the role of PGE2 in IL-1 regulation
has been further demonstrated by restoration of IL-1
release by addition of indomethacin to the assay
system2 9 .

Although not examined in this experiment,

defective or depressed production of arachidonic acid
metabolites may be responsible for high spontaneous IL-1
release from blood monocytes similar to that seen in
alveolar

in sarcoidosis.2

The intense thymocyte proliferative responses
obtained by supernatants from johnin stimulated monocytes
in the control cattle may be attributed to certain
immunoreactive substances of mycobacterial origin known
to be potent inducers of IL-1.

Muramyl dipeptide is a

constituent of most if not all mycobacterial cell walls
which has been shown to induce IL-1.15'54

Trehalose

dimycolate alone or in conjunction with muramyl dipeptide
has also been shown to increase production of a thymocyte
mitogenic protein,54
1.

which is probably analogous to IL-

Increased (P<0.05) but lower response to ML bovis PPD

than johnin may represent differing amounts of these
immunoreactive agents in these two organisms, although
this has not been substantiated.
Keyhole limpet hemocyanin is known to possess dose
dependent mitogenic properties for murine lymphocytes25.
This may account for the moderate responses seen in the
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control group with KLH.

A second explanation, still to

be demonstrated, may be that KLH shares similar properties with
some phorbol esters.

Phorbol esters such as 10-0-

tetradecanoyl-phorbol-13-acetate have been shown to
induce lectin-driven T-cell proliferation independent of
accessory cells and

i l -1.7 '10'1 7 '22

Sensitization was confirmed in the control cattle by
positive intradermal reactions, lymphocyte blastogenesis
(LB), and migration inhibition factor (MIF) assay
(chapter 2).

The infected cattle showed no evidence of

sensitization using these methods, although the same
doses of sensitizing antigen were used in both treatment
groups.

Anergy, known to occur in bovine

paratuberculosis,4 '11 may provide an explanation for in
vivo sensitization failure in infected cattle.
On initial consideration it may be expected that if
a positive response to a sensitizing antigen is obtained
in LT and MIF assays, then an increase in IL-1 release
should also be expected, however this is probably not the
case.

In a study by Chatila et al8 it has been shown

that the necessary requirment for resting T-cell
proliferation is contact by the accessory cell or
monocyte.

Interleukin-1 alone could not promote mitogen

driven proliferation of purified T-cell cultures.

With

suboptimal concentrations of monocytes (0.1%), exogenous
IL-1 increased lymphocyte proliferative responses in a

dose dependent manner.

Higher concentrations of

mononcytes, similar to that seen in peripheral blood,
produced lymphocyte proliferative responses

independent

O

of the concentration of exogenous IL-1.

It was also

shown that monocyte contact is essential for lymphocyte
proliferation.

This may be due to surface associated IL-

nc

,

l^J or possibly a currently unknown mechanism.

In m

vitro assay systems such as LT and MIF the necessary
accessory cell-T-cell contact is established with optimal
concentrations of monocytes and the results are not
dependent on secreted IL-1.
The results indicate that there may be an abnormal
regulatory mechanism for IL-1 secretion in bovine
paratuberculosis.

This may reflect abnormalities in

arachidonic acid metabolism or some other cytokine yet to
be identified as a modulator of IL-1.

Alternatively

spontaneous IL-1 release may be the result of chronic
activation due to the large antigenic burdens in cattle
infected with WL_ paraTB.

TABLE 1.

Mean Mouse Thymocyte Proliferation By Monocyte
Supernatants In The Presence Of Con A
Before Sensitization

Infected Group

Antigen

cpma

media

SIb

Noninfected Group

SI

cpm

1,185e

10,191

1.000

8,158

0.866

17,172

14.501*e

KLH

13,363

1.299

8,080

6.786*e

PPD

12,250

1.210

7,391

6.235*e

LPS

24,222

2.400*

9,987

8.377*e

johnin

1.000

aData expressed is the mean cpm of triplicate assays from
the 3 animals in each group. SD did not exceed 10% of the
mean.

Only data of the dilution which gave the highest

cpm is shown (1:8).
bThe mean stimulation index (SI) was calculated by
dividing the mean of each antigen cpm by the mean of the
media control for each animal. SD did not exceed 10% of
the mean.
ft

P<0.05/ media comparison.

eP<0.05, group comparison.
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TABLE 2.

Mean Mouse Thymocyte Proliferation By Monocyte
Supernatants In The Presence Of Con A
After Sensitization

Infected Group

Antigen

Noninfected Group

cpma

SIb

cpm

SI

Media

2,257

1.000

453e

johnin

1,683

0.776

6,136

13.552*e

KLH

2,992

1.333

2,758

6.110*e

PPD

3,110

1.412

3,075

6.790*e

LPS

5,202

2.296

3,572

7.884*e

1.000

aData expressed is the mean cpm of triplicate assays form
the 3 animals in each group. SD did not exceed 10% of the
mean.

Only data of the dilution which gave the highest

cpm is shown (1:8).
bThe mean stimulation index (S I ) was calculated by dividing
the mean of each antigen cpm by the mean of the media
control for each animal.
mean.
P<0.05, media comparison.
eP<0.05, group comparison.

SD did not exceed 10% of the
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CHAPTER 4

INTERLEUKIN-2 PRODUCTION IN CHRONIC BOVINE
PARATUBERCULOSIS

Abstract
Interleukin-2 (IL-2) production from peripheral blood
mononuclear cells was measured in cattle naturally
infected with Mycobacterium paratuberculosis and in
healthy control cattle using a Concanavalin A induced
blast cell proliferation assay.

Production of IL-2 was

significantly reduced in infected animals when peripheral
blood mononuclear cells were stimulated with Con A.
Animals were sensitized with

paratuberculosis

bacterin, live Mj_ bovis BCG and keyhole limpet hemocyanin
in Freund's incomplete adjuvant and IL-2 production re
evaluated.

Infected animals showed no difference in IL-2

production after sensitization while healthy animals
significantly increased production to the sensitizing
antigens.

These data indicate that cattle naturally

infected with Mycobacterium paratuberculosis have a
decreased ability to produce IL-2 in response to Con A
and that sensitizing doses of mycobacterial and foreign
antigens do not increase IL-2 production in response to
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those antigens.

Defective IL-2 production or the

presence of suppressor substances may account for
these observations and may contribute to disease
persistance in these animals.

Introduction
Bovine paratuberculosis is a chronic enteric disease
caused by infection with Mycobacterium paratuberculosis
(M. paraTB).6

The disease is prevalant throughout the

United States and results in significant economic
losses.6 '17

The host immune status with respect to

production of soluble immuno-inflammatory agents
(interleukins, interferons, prostanoids, etc.)

has been

ignored in paratuberculosis with the exception of in
vitro assays such as migration inhibition1 and lymphocyte
blastogenesis^'11,12 which measure cytokine production
indirectly and not quantitatively.

Quantitative analysis

of these mediators should afford a better understanding
of the disease and the immune defect responsible for
persistance of infection.
Interleukin-2 (IL-2) is a soluble lymphokine which
functions to enhance proliferative responses and clonal
expansion of activated lymphocytes.
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Antigenic,

mitogenic, or alloantigenic stimulation of lymphocytes
results in IL-2 release and IL-2 receptor
expression.6,26'20

Other serum factors such as

transferrin are required to drive IL-2 stimulated T-cells
through the S-phase of growth.2/29

It

a iso

j l -2

which

promotes transferrin receptor expression on activated Tcells.^
Maintainence of the proliferative response in
activated T-cells serves as the basis for IL-2 assays.^
This feature has also been the important factor in recent
advances in propagation of cloned T-cell lines with
specific antigen reactivity and cells which selectively
produce large amounts of specific lymphokines.3
91

Bovine IL-2 has been characterized recently. A
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis and chromatofocusing revealed the
presence of three active molecular species which support
long-term growth of Con A or mixed lymphocyte reactionactivated bovine T-cells.

Cortisol has also been shown

to suppress IL-2 in the bovine both in vitro and in vivo.-*
The following data represent an initial evaluation of IL2 production in cattle with chronic paratuberculosis.

Materials and Methods
Animals:
Three adult Brahman-cross cattle diagnosed positive
for bovine paratuberculosis by rectal biopsy, ileal
biopsy and by enzyme-linked immunosorbent assay31 were
donated to the Louisiana State University School of

Veterinary Medicine by local cattle producers.

These

animals had a history of weight loss and intermittant
diarrhea of at least one year. In addition, 3 non
infected healthy cattle were selected at random from the
School of Veterinary Medicine teaching herd.

Fecal

cultures from control animals using Herrold's egg-yolk
media with and without 2 y.g/ml mycobactin J (Allied Labs,
Ames,IA) were negative after 6 months incubation.

A

single healthy adult cow was selected at random as a
blast cell donor for all IL-2 assays.

Media and Reagents
The medium used for all cell cultures consisted of
RPMI 1640 (GIBCO Laboratories, Chargin Falls, OH)
supplemented with 4 mM L-glutamine and 10% fetal calf
serum (FCS) without antibiotics (complete medium).
Phosphate-buffered saline (PBS), pH = 7.4 was used as a
washing solution.
hemocyanin (KLH)

Concanavalin A (Con A), Keyhole limpet
(Sigma Chemical Co., St. Louis, MO),

johnin and Mycobacterium bovis (M. bovis) PPD (Veterinary
Services Laboratory, Ames, IA) were diluted to
appropriate concentrations in complete media.

Freshly

prepared [3H]thymidine in complete media was used to
assess proliferative responses.

Animals from both groups

were sensitized by subcutaneous injections of 800 mg KLH
in Freund's incomplete adjuvant (Sigma Chemical Co., St.

Louis, MO), 0.5 ml heat-killed MU. paraTB bacterin (Fromm
Laboratories, Grafton, WI) and 6 X 108 live £L_ bovis BCG
(Trudeau Institute, Saranac Lake, NY)

Blood Mononuclear Cells
Heparinized whole blood (40 ml) was collected by
venapuncture and diluted 1:1 with PBS. An equal volume of
Histopaque-1.083 (Sigma Chemical Co., St. Louis, MO) was
slowly injected underneath the blood using a 6 in, 18 ga
needle.

The blood-Histopaque gradient was centrifuged at

1000 X g for 45 min and the mononuclear cell band at the
interface was harvested and the cells washed three times
with PBS.

Platelet contamination was minimized by

differential low speed centrifugation during washing (250
X g for 10 min).

The cells were suspended in complete

medium to a final concentration of 4 X 106/ml.

Cell

viability was >95% using trypan blue exclusion.

Preparation of IL-2 Containing Supernatants
Preparation and assay of IL-2 containing supernatants
were performed by the method of Oldham et al with some
modification. ^

Mononuclear cells (2 ml) were placed in

wells of a 24 well flat bottom plate (Corning Glass
Works, Corning, NY).

The cells from each animal were

cultured with 200 y.1 of one of the following; 500 \ig/ml
Con A, 100 ug/ml johnin,

100 ug/ml ML bovis PPD, 100

y.g/ml KLH and complete media.

The cells were incubated

in a humidified atmosphere for 1 hr at 37°C with 5% CO2 .
The cell suspensions were harvested (200 X g for 10 min)
and the cells washed once with PBS (200 X g for 10 min)
and resuspended in complete medium at a concentration of
4 X 106/ml.

The wells were rinsed twice with 3 ml of PBS

and the cells returned to their respective wells.

The

cells were incubated for 24 hrs under the same conditions
as above and the supernatants harvested and maintained at
-60°C until assayed (within 2 weeks).

Preparation of Con A Blasts
Peripheral blood mononuclear cells were collected as
above and suspended to a final concentration of 2 X
106/ml in complete media containing 5 ug/ml Con A.

After

incubation for 5 days under the same conditions as above,
the cells were gently pelleted (200 X g for 10 min),
washed once with PBS and suspended in complete media at a
concentration of 2 X 106/ml.

IL-2 Assay
The Con A blasts (100
96 well microtiter plate.

ul)

were placed in wells of a

Supernatants containing IL-2

were thawed and two-fold dilutions prepared to 1:64.

The

dilutions were added to triplicate wells containing the
blast cells and incubated for 36 hrs.

The cells were

q
pulsed with 0.5 y.Ci [JH ]thymidine and harvested onto
glass fiber disks 18 hrs later using a semi-automated
cell harvester (Skranton Inc., Sterling, V A ) .

The disks

were dried overnight at 60°C and placed in scintillation
vials to which was added 3 ml of scintillation cocktail
(Fluoralloy™, Beckman Instruments, Fullerton, CA).

The

vials were placed in the dark overnight to minimize
inherent chemiluminescence.

Counts were made for 2 min

on a Packard Tri-Carb 4640 beta counter (Packard
Instrument Co., Downers Grove, IL).

Statistical Analysis
Wilcoxon's rank sum test was used to identify
diffrences using a dilution (1:4) which gave the highest
blast cell proliferative response.

A difference

was considered significant at P<0.05.

Results
Con A blast proliferation induced by IL-2 containing
supernatants was significantly (P<0.05) lower for
infected cattle versus non-infected cattle with respect
to Con A stimulation before sensitization (table 1), and
after sensitization (table 2).

The Con A, johnin, and

PPD responses in the infected group was significantly
(P<0.05) higher than the media control within that group
before and after sensitization.

Proliferative responses

obtained from non-infected and infected animals were
highest with Con A stimulation. No significant (P>0.05)
effect was seen with supernatants obtained by KLH
stimulation in both groups before sensitization.

The

infected group showed significant differences between
johnin and tL bovis PPD when compared to the non-infected
group after sensitization.

There was no significant

(P>0.05) difference in the results obtained post
sensitization in the infected group (table 2).

The non-

infected cattle had significantly (P<0.05) increased IL-2
production in response to KLH, johnin, and
after sensitization.

bovis PPD

No significant (P>0.05) alteration

was observed in the Con A response after sensitization in
the non-infected group.

The KLH, johnin, PPD, and Con A

responses were significantly (P<0.05) greater in the noninfected group in comparison to the infected group after
sensitization.

Sensitization was confirmed in the non-

infected cattle by positive migration inhibition,
lymphocyte stimulation, and skin test responses to the
sensitizing antigens.

The infected group failed to

become sensitized based on the same assays (Chapter 2).

Discussion
In addition to T-cell proliferation, IL-2 has several
other known functions such as induction of lymphokine
activated killer cells which efficiently lyse a variety

of autologous and allogeneic tumor cells.24
Enhanced cytotoxicity of human monocytes has also been
described as a function of IL-2.®'16
The ability of T-cells to produce IL-2 has not been
previously investigated in bovine paratuberculosis.
Comparisons of IL-2 production can be made with
other mycobacterial diseases in which this lymphokine has
been examined, such as in leprosy.10'13'19
Bovine paratuberculosis, like leprosy, often results
in diffuse granulomatous disease.6,23

Lepromatous

leprosy patients are known to have deficient T-cell
responses to

leprae but not to other antigens while

patients with tuberculoid leprosy have strong T-cell
responses to NL leprae.26/28

It was previously indicated

that this unresponsiveness was related to a deficiency in
IL-2 production and that proliferative responses to M.
leprae could be induced by an IL-2-rich T-cell
conditioned media.10

This finding was disputed when it

was demonstrated that failure of T-cells from lepromatous
patients to respond to

leprae was due to a defective

IL-2 receptor expression mechanism. Receptor expression
was not reversed by IL-2 or IL-1 even though IL-1 had
been shown to induce IL-2 receptor expression.13/10
Another study showed that T-cell unresponsiveness to M.
leprae could be reversed by incubation of the T-cells in
simple media in the abscence of

leprae antigen for 48

1

ft

hrs. °

This phenomenon was explained by the induction

of a CD4+ suppressor cell by

leprae.

Cattle with paratuberculosis, in contrast to human
patients with lepromatous leprosy, have positive,
although variable, lymphocyte proliferative responses
with in vitro exposure to johnin and other mycobacterial
antigens.4 '**'*2

it is only in the terminal stages of

the disease when non-specific anergy is present that
indicators of cell mediated immunity such as skin
reactivity are diminished.® The criteria (weight loss and
intermittant diarrhea of one year duration) used in this
experiment to stage the animals with respect to disease
spectrum does not reflect immune status of the host.
Whether chronically infected and anergic animals or
recently infected animals respond similarly with respect
to IL-2 production is not known.
These data indicate that cattle with chronic bovine
paratuberculosis have a decreased capacity to produce IL2 in response to Con A and sensitizing antigens.

Human

IL-2 production can be inhibited by muramyl dipeptide, a
known constituent of mycobacteria*4 '*®

The mechanism of

this suppression has been shown to be mediated by
suppressor T-cells and prostaglandins, ie, PGE2 .*4 '*5
Muramyl dipeptide inhibition of Con A induced blood
mononuclear cell proliferation was due at least in part
to suppression of IL-2.*4 '*®

The suppression of IL-2 in

cattle with paratuberculosis may be due to mycobacterial
components such as muramyl dipeptide or other soluble
products derived from the tremendous number of organisms
present in vivo.

Alternatively, these and other

mycobacterial constituents or products may induce
suppressor substances which inhibit lymphocyte reactivity
as described for lepromatous leprosy2^'26.

Table 1.

Mean Con A Blast Proliferative Responses By

Blood Mononuclear Cell Supernatants Containing IL-2
Before Sensitization
Infected

Antigen

Non-infected

cpma

SIb

cpm

SI

Media

750

1.00

976

1.00

PPD

3,773

5.03*e

1,497

1.53

johnin

4,477

5.96*e

1,605

1.64

KLH

978

1.30

1,821

1.87

Con A

8,675

11.56*e

30,331

31.08*

aRepresents the mean cpm of triplicate assays from
the 3 infected cattle
mean.

SD did not exceed 10% of the

Only data from the dilution which gave the

highest cpm is shown (1:4).
bThe mean stimulation index was calculated by dividing
the mean of each antigen cpm by the mean of the media
control from each animal.
P<0.05, media comparison.
eP< 0.05, group comparison.

Table 2.

Mean Con A Blast Proliferative Responses By

Blood Mononuclear Cell Supernatants Containing IL-2
After Sensitization
Infected

Antigen

cpma

Non- Infected

SIb

cpm

SI

Media

1,116

1.00

835

1.00

PPD

5,267

4.72

7,997

9.57*e

johnin

6,003

5.38

9,815

11.75*e

KLH

1,139

1.02

10,363

12.41*e

Con A

8,897

7.97

22,570

27.03*8

•Ig

R e p r e s e n t s the mean cpm of triplicate assays from
the 3 infected cattle.

SD did not exceed 10% of the mean.

Only data from the dilution which gave the highest cpm is
shown (1:4).
bThe mean stimulation index was calculated by dividing
the mean of each antigen cpm by the mean the media
control for each animal.
*P<0.05, media comparison.
eP<0.05, group comparison.
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CHAPTER 5

INCREASED PRODUCTION OF INTERLEUKIN-2 IN CATTLE WITH
CHRONIC BOVINE PARATUBERCULOSIS BY DIALYZABLE LYMPH NODE
EXTRACTS CONTAINING TRANSFER FACTOR

Abstract
Bovine transfer factor specific for Mycobacterium
paratuberculosis and keyhole limpet hemocyanin was
prepared from lymph node dialysates and administered to
three cattle with chronic bovine paratuberculosis.
Cutaneous delayed hypersensitivity, lymphocyte
blastogenesis, migration inhibition, interleukin-1
release and interleukin-2 production were measured in
response to M^ bovis PPD, johnin, and keyhole limpet
hemocyanin before and after treatment with the transfer
factor.

There was no change in cutaneous delayed

hypersensitivity after transfer factor treatment.

No

alterations in histopathologic features of pre- and post
treatment sections of ileum were noted.

Transfer factor

treatment increased inhibition of migration of
mononuclear cells and interleukin-2 production to johnin
and KLH.

There was no effect on lymphocyte blastogenesis

and release of interleukin-1 by blood monocytes.
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These data suggest that cattle with chronic bovine
paratuberculosis may benefit from transfer factor therapy
and that the effects of transfer factor are partially
mediated by an increase in interleukin-2 production.
Introduction
Bovine paratuberculosis is a chronic wasting disease
produced by enteric infection with Mycobacterium
paratuberculosis.12

Persistance of disease results from

inability of the infected host to rid itself of the
infection.

This implies that there is a defect in cell

mediated immunity.

Blood monocytes and monocyte-derived

macrophages from non-infected cattle have been shown to
be unable to effectively kill the organism and allow
intracellular proliferation.3 '48

A deficient T-cell

response (decreased killer cell activity and interferon
production) could explain why infected cattle cannot
eliminate the organism.

It has been suggested that

cattle with paratuberculosis may benefit from transfer
factor (TF) therapy.24
Since the discovery of TF by Lawerence,26,27 v iafcie
leukocytes, leukocyte extracts, or dialysates of
leukocyte extracts have been used to transfer delayed
hypersensitivity to previously unsensitized individuals.
Some of the clinical syndromes treated with transfer
factor have included cancer immunotherapy,33'39 internal
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parasitism,

O0

lupus erythematosus,

Of)

sarcoidosis,

01

v a c c i n i a , ^ coccidiomycosis,^ tuberculosis,44
7

lepromatous leprosy , and recently intestinal
cryptosporidiosis in patients with human immunodeficiency
virus infections.24

These treatment results have been

variable, although often promising.
Leukocyte lysates which contain inducer factors
and suppressor factors have been obtained from T-helper
Of)

and T-suppressor cells, respectively. u

Much of the

variability noted in clinical applications has probably
been due to the fact that the crude lysates contained
mixtures of both factors.14'21'28,29

The suppressor

factor has been used for the modulation of diseases such as
lupus erythematosis and autoimmune thrombocytopenic
purpura characterized by an undesirable immune
response.4,20
Certain chemical and biological properties of TF have
O

0

been well documented. u

In dialysates from human cells

the active component is usually present in the 3.5 to
12kD molecular weight range, and has been shown to bind
to specific antigen and anti-la antibody.^

The inducer

factor is absorbed by T-suppressor cells and
macrophages.

C.

Bovine TF specific for Mycobacterium

tuberculosis PPD has been characterized as an
oligoribonucleopeptide with a molecular weight of between
1.1 to 3.0kD.44

It has been postulated that TF may be a

dialyzable fragment of a T-helper cell receptor which
equips the non-committed immunocyte with an antigen
binding moiety.30
The duration of effect of treatment with TF has not
been well documented in every case.

In a study using

TF as a preventative measure for varicella-zoster virus
infection, it was found that antibody titers of TFtreated patients developed after virus exposure and
remained as high as those in infected individuals for 17
months.^3

The TF-treated group also had an active cell

mediated immunity for the same period of time as
demonstrated in vitro and by skin tests.
The effect of TF has not been previously evaluated in
bovine paratuberculosis, but its effect on other
mycobacterial diseases has been examined.

Lepromatous

leprosy patients were evaluated using TF which was
prepared from donors selected on the basis of positive
skin reactivity and in vitro lymphocyte responses.^
Infected recipients were initially negative to skin tests
with lepromin.

After administration of TF the recipients

became skin test positive after the first or third days.^
In vitro lymphocyte blastogenesis results were not
altered.

The recipients experienced erythema of the

cutaneous lesions and occasionally fever.

There was no

alteration in histologic characteristics of the lesions
when compared to pre-TF lesions.

The majority of the

recipients reverted to a skin test negative status about
25 months after TF administration.

These changes,

although short-lived are extremely promising when it is
considered that only one dose of TF was given.

In

patients with tuberculosis which was unresponsive to
conventional tuberculostatic drugs, TF has been

an

important adjunct in therapy. 44,47

Materials and Methods
Animals
Three naturally infected Brahman cross-bred cattle
were donated to the Louisiana State University Veterinary
Teaching Hospital by Louisiana cattle producers.

The

cattle were confirmed as positive for paratuberculosis by
ileal and mesenteric lymph node biopsies and positive
AC

ELISA test results. °

The cattle were housed on concrete

and fed Bermuda grass hay ad libitum.

Two healthy

Brahman calves (180 kg body weight) were purchased from a
local stockyard for production of transfer factor.

Experimental Design
Biopsies of the ileum and and mesenteric lymph nodes
were taken from each animal and the surgical sites
allowed to heal for at least three weeks.

Assays were

performed for IL-1, IL-2, migration inhibition factor
(MIF), lymphocyte blastogenic (LB) responses and
cutaneous hypersensitivity in response to KLH, ML bovis
PPD and johnin

prior to treatment with transfer factor.

Transfer factor was administered weekly for three weeks.
At the end of the treatment period all assays were
repeated and necropsies performed.

Skin Testing
The cervical area of each cow was clipped and double
skin thickness measured prior to injection.

Intradermal

injections of 0.2 ml containing 1000 ug johnin, M.
bovis PPD and KLH in PBS were given to each cow.
negative control PBS was used.

For a

The change in double skin

thickness was recorded after 48 hrs.

The cattle were

retested using the contralateral cervical area after
transfer factor treatment.

Media and Reagents
The medium used for most assays consisted of RPMI
1640 (GIBCO Laboratories, Chargin Falls, OH) supplemented
with 4 mM L-glutamine and 10% fetal calf serum (FCS)
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without antibiotics (complete culture medium, CCM).
Dulbecco's MEM (GIBCO Laboratories, Chargin Falls, OH)
was used in the migration inhibition assay.

Phosphate-

buffered saline (PBS), pH = 7.4, was used as a washing solution.
Phytohemaglutinin (PHA), Cocanavalin A (ConA), keyhole
limpet hemocyanin (KLH)

(Sigma Chemical Co., St. Louis,

MO), johnin and Mycobacterium bovis (M. bovis) PPD
(Veterinary Services Laboratory, Ames, IA) were diluted
to appropriate concentrations (as determined by previous
dose response trials) in CCM or PBS.

Freshly prepared

[^ H ]thymidine in CCM was used to assess proliferative
responses in IL-1, IL-2 and LB assays.

Mycobacterium

paratuberculosis bacterin (Fromm Laboratories,

Grafton,

WI) and KLH in Freund's incomplete adjuvant (Sigma
Chemical Co.,

St. Louis, MO) were used to innoculate the

donor calves for transfer factor preparation.

All assays

were performed before and after transfer factor
treatment.

Blood Mononuclear Cells
Heparinized whole blood was collected by
venapuncture and diluted 1:1 with (PBS).

An equal volume

of Histopaque-1.083 (Sigma Chemical Co., St. Louis, MO)
was slowly injected underneath the blood using a 6 in, 18
ga needle.

The blood-Histopaque gradient was centrifuged

at 1000 X g for 45 min and the mononuclear cell band at

the interface was removed and the cells washed three
times with PBS.

Platelet contamination was minimized by

differential low speed centrifugation during washing (250
X g for 10 m i n ) .

The cells were suspended in complete

medium to a final concentration of 2-5 X 106/ml depending
on the assay to be performed.

Cell viability was >95%

using trypan blue exclusion.

Preparation of Adherent Cells for IL-1
Gradient-separated mononuclear cells were suspended
in CCM at a concentration of 5 X 10^/ml.

The cells were

incubated in a 75 cm2 plastic culture flask (15 to 20 ml
per flask) for 1 h.

Non-adherent cells were

vigorously washing 5 times with PBS.

removed by

Adherent cells were

removed using a plastic cell scraper (Costar, Cambridge,
MA) and suspended in CCM containing 2% FCS at a
concentration of 1 X 106/ml (trypan blue exclusion showed
a viability of >90%).

The recovered cell suspension

consisted of >95% monocytes with slight platelet
contamination.

Aliqouts of adherent cells (1ml) were

placed in wells of a 24 well plate (Corning Glass Works,
Corning, NY).

Preparation of IL-1 Containing Supernatants:
To 1 ml aliquots of adherent cells from each animal

was added an equal volume of one the following; media
with 2% FCS, 50 ug/ml

johnin, 50 ug/ml M^ bovis PPD, 50

ug/ml KLH, and 20 ug/ml LPS.
hrs at 37°C and 5% CC>2 .

Cells were cultured for 24

Supernatants were harvested and

maintained at -60°C until assayed (within 2 weeks).

IL-1 Assay:
The assay for IL-1 followed the guidelines as
reviewed by Gearing, et al1^ with minor modifications.
Adherent cell supernatants were thawed and serial two
fold dilutions were made with media to 1:64.

The

thymuses from 6 wk old C3H/HeJ mice (Jackson
Laboratories, Bar Harbor, ME) were used in all assays.
Each thymus was aseptically removed and teased apart in 5
ml of CCM.

The thymocytes and thymic tissue were allowed

to sediment at 1 X g for ten minutes.

About 4 ml of cell

suspension were withdrawn and adjusted to a final
concentration of 5 X 10^/ml in media containing 10% FCS
and 1.5 ug/ml Con A.
exclusion was >95%.

Viability assesed by trypan blue
Thymocytes in 100 ul of media were

added to the wells of a 96 flatbottom well culture plate.
An equal volume of diluted adherent cell supernatant was
added to the thymocyte cultures.

After incubation for 48

hrs, 0.5 uCi/50ul [3H ]thymidine in CCM was added to each
well.

Cells were harvested after 18 hr onto glass fiber

disks a semi-automated cell harvester (Skranton Inc.,

Sterling, V A ) .

The disks were dried overnight at 60°C

and placed in scintillation vials to which was added 3 ml
of scintillation cocktail (Fluoralloy™, Beckman
Instruments, Fullerton, CA ) .

The vials were placed in

the dark overnight to minimize inherent
chemiluminescence.

Counts were made for 2 min on a

Packard Tri-Carb 4640 beta counter (Packard Instrument
Co., Downers Grove, IL).

All assays were performed in

triplicate. Supernatants were intermittantly screened for
interleukin-2 as described below. Interleukin-2 activity
using this assay was negligible.

Preparation of IL-2 Containing Supernatants
Preparation and assay of IL-2 containing supernatants
were performed by the method of Oldham et al88 with minor
modification.

Mononuclear cells were suspended in CCM

at a concentration of 4 X 106/ml and 2 ml of cells were
placed in wells of a 24 well plate (Corning Glass Works,
Corning, N Y ) .

The cells from each animal were cultured

with 200 y.1 CCM containing one of the following; 500
ug/ml Con A, 100 ug/ml johnin,

100 ug/ml NL bovis PPD,

100 ug/ml KLH or CCM without additive.

The cells were

incubated in a humidified atmosphere for 1 hr at 37°C
with 5% CC>2 .

The cell suspensions were harvested and the

cells washed once with PBS.

The wells were rinsed twice

with 3 ml of PBS and the cells returned to their

respective wells.

The cells were incubated for 24 hrs

under the same conditions as above and the supernatants
were harvested and maintained at -60°C until assayed
(within 2 weeks).

Preparation of Con A Blasts
Blood was collected from a single healthy cow and
used to prepare Con A blasts for each IL-2 assay.
Peripheral blood mononuclear cells were collected as
above and suspended to a final concentration of 2 X
£
10°/ml in CCM containing 5 p.g/ml Con A. After incubation
for 5 days under the same conditions as described above,
the cells were gently pelleted (200 X g for 10 min),
washed once with PBS and suspended in CCM at a
concentration of 2 X 106/ml.

IL-2 Assay
The Con A blasts (100 y.1) were placed in wells of a
96 well microtiter plate.

Supernatants containing IL-2

were thawed and two-fold dilutions prepared to 1:64.

The

dilutions were added to triplicate wells containing the
blast cells and incubated for 36 hrs.

The cells were

pulsed with 0.5 uCi [-^H]thymidine and harvested after 18
hrs incubation.
described above.

Scintillation counting was done as

Lymphocyte Blastogenesis
Gradient-separated mononuclear cells were suspended
in CCM at a concentration of 2 X 10®/ml and 100 ul
aliquots were placed in the wells of a 96 flatbottom well
plate.

To triplicate wells was added 100 ul volumes of

CCM with one of the following: 50 ug/ml johnin, 50 ug/ml
M. bovis PPD, 30 ug/ml KLH, 25 ug/ml PHA, or CCM without
additives.

The cells were incubated for 72 hrs., pulsed

with 0.5 uCi/50ul [® ]thymidine, and collected after 18
hrs and handled as described above.

Migration Inhibition Assay
A microagarose droplet assay as described by
Harrington and Stastny was used with minor
modifications.19

Cell pellets containing 10® gradient-

separated mononuclear cells were combined with 100 ul of
2 X Dulbecco’s MEM with 20% FCS and 100 ul of 0.4%
agarose in distilled water.

The cells, media and agarose

were gently mixed and 1 ul droplets were placed in the
center of the wells of a 96 flatbottom well

plate.

The

plate was refrigerated (4°C) for 10 min prior to the
addition of antigens.

To triplicate wells 100 ul volumes

CCM was added containing one of the following: 50 ug/ml
johnin, 50 ug/ml M^_ bovis PPD, 50 ug/ml KLH, 25 ug/ml PHA
and CCM without additive.

After 48 hrs incubation each

well was photographed and a 5 X 7 print made.

The two

most symmetrical droplets from each treatment were
selected and the distance was measured from the edge of
the droplet to the edge of the cell migration zone.
Three random measurements were made from each of the
selected droplets and the mean and standard deviation
were calculated.
migration:

Data were expressed as % inhibition of

[(mean migration distance of media control) -

(mean migration distance of antigen)/(mean migration
distance of media control)] X 100.

A 20% inhibition of

migration was considered a positive MIF assay reaction.-*-1

Preparation and Administration of Crude TF
Two calves were inoculated with 8.0 mg KLH in
Freund's incomplete adjuvant and 1 ml Mycobacterium
paratuberculosis bacterin (twice the manufacturers
reccomended dose).

After three weeks, sensitization was

confirmed by positive (>5 mm increase) skin test
reactivity to johnin and KLH.

The calves were killed and

prescapular, submandibular, prefemoral, popliteal,
cervical, tracheobronchial, mesenteric, perirenal, and
pelvic lymph nodes removed.

The lymph nodes were minced

and pressed through a 40 mesh screen.

The resulting cell

suspension (5 X 108/ml) was incubated in Hank's balanced
salt solution for 4 hrs at which time the suspension
became acidic.

The supernatants were harvested and an

Amicon DC-10 hollow fiber concentrator in dialysis mode

was used to collect the fraction which contained material
of lOkD molecular weight and less (designated crude TF).
This fraction was frozen in 10 ml aliquots and maintained
at -60°C until use (within 5 weeks).

Each infected

animal was given 10 ml of crude TF subcutaneously at
weekly intervals for three weeks.

Necropsy
Treated animals were killed and sections of intestine
adjacent to the original biopsy site and a regional
mesenteric lymph node were fixed in 10% neutral buffered
formalin, embedded in methacrylate, sectioned, mounted on
glass slides,

and examined by light microscopy.

Hematoxylin and eosin and acid-fast stained sections were
examined in pre- and post-treatment tissues.

Statistics
Wilcoxon's rank sum test was used to compare data for
the IL-1 and IL-2 assays.

Lymphocyte blastogenesis,

migration inhibition, and skin test data were compared
with Student's t-test.

Results were considered

significant at P<0.05.

Results
The administration of TF had no effect on skin test

reactivity (P>0.05) in this experiment (table 1).
Migration inhibition and IL-2 production were
significantly increased (P<0.05) using KLH (figure 1) and
johnin (tables 2 and 3, respectively).

There was no

difference in LB responses with johnin, KLH, and PHA
before or after TF treatment (table 4).

The high

blastogenic responses and inhibition of migration in
response to M^ bovis PPD noted before TF treatment were
significantly (P<0.05) reduced (tables 2 and 4).
Increases (P<0.05) in IL-2 production were seen only with
johnin and KLH, with no change in response to Con A and
M. bovis

were not affected.

Production of IL-1 was

unaffected (P>0.05) by administration of TF (table 5).
The cpm values and stimulation indices for IL-1 release
were similar to those obtained previously (Chapter 3).
Sections of ileum and mesenteric lymph node were similar
before and after TF treatment.

Both contained a marked

granulomatous reaction in the lamina propria and
submucosa.

Moderate to marked numbers of acid-fast

bacilli were present in macrophages and multinucleated
giant cells (figures 2-5).

Discussion
The classic response of TF treatment is the transfer
of cutaneous hypersensitivity to previously nonresponsive i n d i v i d u a l s . 30

Mazahari et al have shown

that

positive cutaneous delayed hypersensitivity in

primates may no be apparent until at least 21 days after
administration of TF although in vitro migration
inhibition was positive between 2 and 14 days.26

This

may account for negative skin test results in this
experiment as skin test reactions were examined only at
21 days after the onset of TF administration.
In general, lymphocyte blastogenesis and monocyte
migration inhibition have been considered good correlates
of in vivo cell mediated immunity transfered by
^ 16,35,40^

some studies, however, indicate this

be true.17,41.

not to

There has been poor agreement between

lymphocyte blastogenesis and cutaneous hypersensitivity
tests in TF recipients.10,16

Usually there is a positive

skin test response with no alteration in lymphocyte
transformation.

Non-specific activities of TF which

affect lymphocyte blastogenesis include augmentation or
suppression of responses to antigens or
mitogens.1/8,9,18,32,43
It is interesting to note that in this experiment a
previously significant blastogenic response to

bovis

PPD was selectively suppressed after TF treatment even
though the TF was not prepared from a known NN bovis
responsive donor.

Monocyte migration inhibition assays

are usually considered a more appropriate in vitro assay
for the evaluation of the TF effects,22 however some

reports indicate the unfractionated (crude) TF-containing
preparations augment non-specific production of migration
inhibition factor.2/25
Indirect evidence indicates that the T-cell is the
target cell for

As

effector cell in cell

mediated immune responses is the monocyte or macrophage,
it would be reasonable to expect that TF acting on the Tcell would modulate the monocyte and macrophage.
Transfer factor preparations have also been shown to
elevate interferon levels.13

This may be the important

communication link between the TF activated lymphocyte
and the macrophage.
The ability of TF preparations to augment or suppress
production of IL-1 and IL-2 has not been previously
examined.

The results of this experiment indicate that

TF augments IL-2 production in response to specific
antigens but does not increase the release of IL-1.

A

generalized (non-specific) increase in IL-2 production
may account for the increased dermal hypersensitivity
seen following TF administration, but would not account
for antigen specificity.

The increase in IL-2 noted in

this experiment was seen only in response to antigens to
which the TF was initially prepared.
The results of this study demonstrate a previously
unreported effect of TF, an increased antigen-specific
production of IL-2.

Although cutaneous hypersensitivity

was not transferred and no lesion alterations were noted
after treatment, the positive responses (increased IL-2
and greater migration inhibition) indicate that cattle
with chronic bovine paratuberculosis may benefit from a
longer duration of treatment with specific TF.
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Table 1.

Delayed Cutaneous Hypersensitivity

in Mycobacterium paratuberculosis-Infected Cattle
Treated With Transfer Factor

Pre-Treatment

Post-Treatment

Change in Skin

Change in Skin

Thickness (mm)

Antigen

Cattle
#1
#2

#3

Thickness (mm)

#1

Cattle
#2

#3

PPD

4.2

3.2

4.4

4.0

3.0

4.5

johnin

5.3

6.6

3.2

4.9

5.9

3.3

KLH

0.2

0.6

1.4

0.3

0.6

1.1

media

0.0

0.0

0.3

0.1

0.0

0.1

mean+SD

mean+SD

PPD

3.93+0.64

3.83+0.76

johnin

5.03+1.72

4.70+1.31

KLH

0.73+0.61

0.67+0.40

media

0.10+0.17

0.07+0.06

No significant difference after transfer factor treatment.
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Table 2. Mean Percent Inhibition of Migration
in Mycobacterium paratuberculosis-Infected Cattle
Treated with Transfer Factor

Antigen

Pre-Treatment

Post-Treatment

PPDb

43.2 + 5.5a

21.3 + 1.8

johnin

33.7 + 1.8

58.1 + 7.1*

KLHC

11.5 + 0.9

52.5 + 6.2*

aMean+SD.
^Derived from Mj_ bo v i s .
cKeyhole limpet hemocyanin.
*P<0.05

Ill
Table 3.

Mean Con A Blast Proliferative Responses By Blood

Mononuclear Cell Supernatants Containing IL-2
From Mycobacterium paratuberculosis-Infected Cattle
Treated With Transfer Factor

Post-Treatment

Pre-Treatment

Antigen

cpma

SIb

cpm

SI

680

1.00

1289

1.92

9,977

14.66*e

1.31

3,763

5.55s

15.02 *

6,980

10.26

Media

512

1.00

PPD

1 ,522

3.02

johnin

2,668

5.30

KLH

634

Con A

7,612

sir

*

aRepresents the mean cpm of triplicate assays from
the 3 infected cattle
the mean.

SD is not greater than 10% of

Only data from the dilution which gave the
<

highest cpm is shown (1:4).
bThe mean stimulation index was calculated by dividing
the mean of each antigen cpm by the mean of the media
control for each animal.
sir

P<0.05, media comparison.

eP<0.05, group comparison.

Table 4.

Mean Lymphocyte Blastogenesis

in Mycobacterium partuberculosis Infected Cattle
Treated With Transfer Factor

Pre-■treatment

Antigen

cpm

Post- treatment

SIa

cpm

SI

857

1.0

642

1.0

10,627

12.6

4,237

7.1

johnin

9,684

11.3

8,089

11.9

KLHC

1,885

1.9

PHAd

20,396

23.3

media
PPDb

1,219

1.7
21.7

12,968

aThe mean SI was calculated by dividing the mean antigen
cpm of triplicate assays from each of the 3 infected
animals by the cpm of the media control.

SD did not

exceed 10% of the mean.
^Derived from M;_ bovis; ckeyhole limpet hemocyanin;
dphytohemaglutinin.
All antigen and mitogen responses are significantly
different than the media control (P<0.05).

No

differences are apparent between pre- and post
treatment data.
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Table 5.

Mean Mouse Thymocyte Proliferation By

Monocyte Supernatants Containing IL-1 In The Presence
Of Con A FromMtcobacterium paratuberculosis-Infected
Cattle Treated With Transfer Factor

Pre-treatment

Antigen

Media

cpma

SIb

Post-treatment

cpm

SI

9,343

1.00

11,022

1.00

PPD

10,177

1.13

11,674

1.02

johnin

10,622

1.20

9,980

0.90

KLH

13,234

1.37

12,609

1.15

LPS

22,701

2.39

21,655

2.01

aData expressed is the mean cpm of triplicate assays form
the 3 animals in each group. SD is not greater than 10%
of the mean.

Only data of the dilution which gave the

highest cpm is shown (1:8).
bThe mean stimulation index was calculated by dividing
the mean of each antigen cpm by the mean the media
control for each animal.
mean.
P<0.05, media comparison.

SD did not exceed 10% of the

Figure 1.

Example of increased migration inhibition in

response to keyhole limpet hemocyanin after transfer
factor treatment.

Media control (top); before treatment

(center); after treatment (bottom).

Figure 2.

Ileal biopsy specimen taken before transfer

factor treatment.

There is a marked accumulation of

macrophages in the lamina propria and submucosa. HE, 200X.

Figure 3.

Section of ileum taken adjacent to the initial

biopsy site after transfer factor treatment.

Lesions

noted are similar to the pre-treatment section. HE, 200X.

Figure 4.

Lymph node biopsy specimen taken before

transfer factor treatment.

There is a moderate to marked

accumulation of macrophages in the cortex.

HE, 200X.

Figure 5.

Mesenteric lymph node specimen taken adjacent

to the initial biopsy site after transfer factor
treatment.

The section is similar to the pre-treatment

biopsy sample.
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CHAPTER 6

THE EFFECTS OF RIFABUTIN (ANSAMYCIN LM 427) IN CATTLE
WITH CHRONIC BOVINE PARATUBERCULOSIS

Abstract
Three cattle with chronic paratuberculosis were
examined for delayed cutaneous hypersensitivity,
macrophage migration inhibition, lymphocyte
blastogenesis, interleukin-1 production and interleukin-2
production in response to johnin,

bovis PPD, and

Keyhole limpet hemocyanin before and after treatment with
rifabutin.

Rifabutin was administered orally at a dose

of 1200 mg daily for 3 weeks.

Sections of ileum and

mesenteric lymph node were examined microscopically
before and after treatment.

By the end of the treatment

period there was a significant increase in skin
reactivity to johnin.

No changes in skin reactivity were

seen with the other antigens.

There was no difference in

interleukin-1 release, interleukin-2 production,
blastogenesis and migration inhibition before and after
treatment.
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Introduction
Bovine paratuberculosis is a chronic enteric
infection caused by Mycobacterium paratuberculosis which
results in diarrhea, weight loss and eventually
death.

Treatment of affected cattle with

antimycobacterial agents, such as clofazimine, has
resulted in drug dependent remission of clinical signs,
however, the cattle continued to shed the organism in
feces even with prolonged duration of treatment (over 300
7 ft 1 1 IQ

days)''°'xx 'x .

Although a cure does not result from the

administration of clofazimine, it may be useful for the
treatment of valuable breeding stock.
Rifabutin (4-deoxo-3,4-[2-spiro-(N-isobutyl-4piperidyl)](1H)-imidazole(2,5-dihydro)-rifamycin S), a
semi-synthetic derivative of rifamycin S, was first
synthesized by Marsili et al.^

This agent and other

related compounds were found to have activity against
Mycobacterium tuberculosis and Mycobacterium aviumcomplex organisms. It also has the advantage of a longer
half-life than other derivatives of rifamycin S, such as
17
rifampin. *

Rifabutin has a broad spectrum of activity

against gram-positive and gram-negative bacteria similar
to rifampin.15

The compound has activity against

rifampin-resistant strains of Mycobacterium tuberculosis
presumably due to the difference in mechanism of action.
Rifabutin interferes with DNA synthesis whereas rifampin

18

inhibits DNA-dependent RNA polymerase. °
The in vivo use of Rifabutin has been primarily
limited to experimental infections and AIDS patients
concurrently infected with mycobacteria.5,6,12,14
Recently, a colony of stumptail macaques was diagnosed as
having Mycobacterium paratuberculosis infection with
lesions similar to ruminant paratuberculosis.^-®

Macaques

treated with rifabutin showed dramatic improvement and
treated animals remained in clinical remission for up to
30 months post-treatment.
Rifabutin has not been previously evaluated as a
potential therapeutic agent for bovine paratuberculosis.
The purpose of this study was to evaluate the use of
rifabutin in bovine paratuberculosis by the comparison of
immunologic parameters and intestinal lesions after
treatment.

Materials and Methods
Animals
Three naturally infected Brahman cross-bred cattle
were donated to the Louisiana State University Veterinary
Teaching Hospital by local cattle producers.

The cattle

were confirmed positive for paratuberculosis by ileal and
mesenteric lymph node biopsies and positive ELISA
test results.2®

The cattle were housed on

concrete and fed Bermuda grass hay ad libitum.

Experimental Design
Biopsies of the ileum and mesenteric lymph nodes were
taken from each animal and surgical sites allowed to heal
for at least three weeks.

Assays were performed for

interleukin-1 (IL-1), interleukin-2 (IL-2), migration
inhibition factor (MIF), lymphocyte blastogenic (LB)
responses and cutaneous hypersensitivity in response to
KLH, IL bovis PPD and johnin prior to treatment with
rifabutin.
three weeks.

Rifabutin was administered daily per os for
At the end of the treatment period the

assays were repeated and necropsies performed.

Media and Reagents
The culture medium used for most assays consisted of
RPMI 1640 (GIBCO Laboratories, Chargin Falls, OH)
supplemented with 4 mM L-glutamine and 10% fetal calf
serum (FCS) without antibiotics (complete culture medium,
CCM).

Dulbecco's MEM (GIBCO Laboratories, Chargin Falls,

OH) was used in the MIF assay.

Phosphate-buffered saline

(PBS), pH = 7.4, was used as a washing solution.
Phytohemaglutinin (PHA), Concanavalin A (Con A), keyhole
limpet hemocyanin (KLH)

(Sigma Chemical Co., St. Louis,

M O ) , johnin and Mycobacterium bovis (M . bovis) PPD
(Veterinary Services Laboratory, Ames, IA) were diluted

to appropriate concentrations (as determined by previous
dose response trials) in CCM or PBS.

Freshly prepared

[JH]thymidine in CCM was used to assess proliferative
responses in IL-1, IL-2 and LB assays.

Rifabutin was a

gift obtained from Adria Laboratories, Columbus, Ohio
(Vernon Verhoeff).

Skin Testing
The cervical area of each cow was clipped and double
skin thickness measured prior to injection.

Intradermal

injections of 0.2 ml containing 1000 y.g johnin, M.
bovis PPD and KLH in PBS were given to each cow.
negative control PBS was used.

For a

The change in double skin

thickness was recorded after 48 hrs.

The cattle were

retested using the contralateral cervical area after
transfer factor treatment.

Blood Mononuclear Cells
Heparinized whole blood was collected by
venapuncture and diluted 1:1 with (PBS).

An equal volume

of Histopaque-1.083 (Sigma Chemical Co., St. Louis, MO)
was slowly injected underneath the blood using a 6 in, 18
ga needle.

The blood-Histopaque gradient was centrifuged

at 1000 X g for 45 min and the mononuclear cell band at
the interface was removed and the cells washed three
times with PBS.

Platelet contamination was minimized by

differential low-speed centrifugation during washing (250
X g for 10 rain).

The cells were suspended CCM to a final

concentration of 2-5 X 10^/ml depending on the assay to
be performed.

Cell viability was >95% using trypan blue

exclusion.

Preparation of Adherent Cells for IL-1
Gradient-separated mononuclear cells were suspended
in CCM at a concentration of 5 X 106/ml.

The cells were

incubated in a 75 cm^ plastic culture flask (15 to 20 ml
per flask) for 1 h.

Non-adherent cells were

vigorously washing 5 times with PBS.

removed by

Adherent cells were

removed using a plastic cell scraper (Costar, Cambridge,
MA) and suspended in CCM containing 2% FCS at a
f.

concentration of 1 X 10 /ml (trypan blue exclusion showed
a viability of >90%).

The recovered cell suspension

consisted of >95% monocytes with slight platelet
contamination.

Aliquots of adherent cells (1ml) were

placed in wells of a 24 well plate (Corning Glass Works,
Corning, NY).

Preparation of IL-1 Containing Supernatants:
To 1 ml aliquots of 1 X 106 adherent cells/ml from
each animal was added an equal volume of one of the
following; CCM with 2% FCS, 50 ug/ml

johnin, 50 y.g/ml M.

bovis PPD, 50 p.g/ml KLH, and 20 ug/ml LPS.

Cells were

cultured for 24 hrs at 37°C with 5% C02 and 100%
humidity.

Supernatants were harvested and maintained at

-60°C until assayed (within 2 weeks).

IL-1 Assay:
The assay for IL-1 followed the guidelines as
reviewed by Gearing, et al^ with minor modifications.
Adherent cell supernatants were thawed and serial two
fold dilutions were made with CCM to 1:64.

The thymuses

from 6 wk old C3H/HeJ mice (Jackson Laboratories, Bar
Harbor, ME) were used in all assays.

Each thymus was

aseptically removed and teased apart in 5 ml of CCM.

The

thymocytes and thymic tissue were allowed to sediment at
1 X g for ten minutes.

About 4 ml of cell suspension was

withdrawn and adjusted to a final concentration of 5 X
106/ml in CCM containing 1.5 ug/ml Con A.

Viability

assessed by trypan blue exclusion was >95%.

Thymocytes

in 100 p.1 of CCM were added to the wells of a 96
flatbottom culture plate.

An equal volume of diluted

adherent cell supernatant was added to the thymocyte
cultures.

After incubation for 48 hrs, 0.5 u.Ci/50ul

[ H ]thymidine in CCM was added to each well.

Cells were

harvested after 18 hr onto glass fiber disks using a
semi-automated cell harvester (Skranton Inc., Sterling,
VA).

The disks were dried overnight at 60°C and placed

in scintillation vials to which was added 3 ml of

scintillation cocktail (Fluoralloy™, Beckman
Instruments, Fullerton, CA).

The vials were placed in

the dark overnight to minimize inherent
chemiluminescence.

Counts were made for 2 min on a

Packard Tri-Carb 4640 beta counter (Packard Instrument
Co., Downers Grove, IL).

All assays were performed in

triplicate. Supernatants were intermittently screened for
IL-2 as described below.

Preparation of IL-2 Containing Supernatants
Preparation and assay of IL-2 containing supernatants
were performed by the method of Oldham et al^3 with minor
modification.

Mononuclear cells were suspended in CCM at

a concentration of 4 X 10®/ml and 2 ml of cells were
placed in wells of a 24 well
Corning, NY).

plate (Corning Glass Works,

The cells from each animal were cultured

with 200 p.1 CCM containing one of the following; 500
ug/ml Con A, 100 ug/ml johnin,

100 jig/ml Mk_ bovis PPD,

100 ug/ml KLH or CCM without additive.

The cells were

incubated in a humidified atmosphere for 1 hr at 37°C
with 5% C02 .

The cell suspensions were harvested and the

cells washed once with PBS.

The wells were rinsed twice

with 3 ml of PBS and the cells returned to their
respective wells.

The cells were incubated for 24 hrs

under the same conditions as above and the supernatants

harvested and maintained at -60°C until assayed (within 2
we eks).

Preparation of Con A Blasts
Blood was collected from a single healthy cow and
used to prepare Con A blasts for each IL-2 assay.
Peripheral blood mononuclear cells were collected as
above and suspended to a final concentration of 2 X
106/ml in CCM containing 5 y.g/ml Con A.

After

incubation for 5 days under the same conditions as above,
the cells were gently pelleted (200 X g for 10 m i n ) ,
washed once with PBS and suspended in CCM at a
concentration of 2 X 106/ml.

IL-2 Assay
The Con A blasts (100 y.1) were placed in wells of a
96 well microtiter plate.

Supernatants containing IL-2

were thawed and two-fold dilutions prepared to 1:64.

The

dilutions were added to triplicate wells containing the
blast cells and incubated for 36 hrs.

The cells were

pulsed with 0.5 y.Ci [ ] thymidine and harvested
after 18 hrs and prepared for beta counting as before.

Lymphocyte Blastogenesis
Gradient-separated mononuclear cells were suspended
in CCM at a concentration of 2 X 10®/ml and 100 ul

aliquots were placed in the wells of a 96 well flat
bottom microtiter plate.

To triplicate wells was added

100 yl CCM with one of the following: 50 yg/ml johnin, 50
yg/ml

bo vis PPD, 30 yg/ml KLH, 25 yg/ml PHA, and CCM

without additive.

The cells were incubated for 72 hrs.,

pulsed with 0.5 yCi/50yl [®H ]thymidine, and collected
after 18 hrs and handled as described (Chapter 2).

Migration Inhibition Assay
A microagarose droplet assay as described by
Harrington and Stastny was used with minor
modifications.4

Cell pellets containing 10® gradient-

separated mononuclear cells was add 100 yl of 2 X
Dulbecco's MEM with 20% FCS and 100 yl melted agarose
(SeaPlaque™, FMC Corporation, Rockland, ME)

The cells,

media and agarose were gently mixed and 1 y.1 droplets
were placed in the center of the wells of a 96 flatbottom
microtiter plate.

The plate was refrigerated (4°C) for

10 min prior to the addition of antigens.

To triplicate

wells 100 y.1 CCM was added containing one of the
following: 50 yg/ml johnin, 50 yg/ml M^ bovis PPD, 50
yg/ml KLH, 25 yg/ml PHA and CCM without additive.

After

48 hrs incubation each well was photographed and a 5 X 7
print was made.

The two most symmetrical droplets from

each treatment were selected and the distance from the
edge of the droplet to the edge of the cell migration

zone was measured.

Three random measurements were made

from each of the selected droplets and the mean and
standard deviation were calculated.
as % inhibition of migration:

Data were expressed

[(mean migration distance

of media control) -(mean migration distance of
antigen)/ (mean migration distance of media control)] X
100.

A 20% inhibition of migration was considered a

positive test.

1

Administration of Rifabutin
The cattle were each given 1200 mg rifabutin orally
in gelatin capsules once daily for 21 days.

Necropsy
Treated animals were killed and sections of intestine
adjacent to the original biopsy site and a regional
mesenteric lymph node were fixed in 10% neutral buffered
formalin, embedded in methacrylate, sectioned, mounted on
glass slides, and examined by light microscopy.
Hematoxylin and eosin and acid-fast stained sections were
examined in pre- and post-treatment tissues.

Statistics
IL-1 and IL-2 production was compared using
Wilcoxon's rank sum test.

Migration inhibition,

lymphocyte blastogenesis, and skin test data were

compared with Student's t-test. Results were considered
significant at P<0.05.

Results
The delayed cutaneous hypersensitivity reaction to
johnin significantly (P<0.05) increased after rifabutin
treatment with no difference (P>0.05) in response to the
other antigens (table 1).

There was a slight increase

(P>0.05) in IL-2 production to johnin stimulation, but no
change was noted with the other antigens (table 2).

No

difference (P>0.05) in IL-1 release was observed before
and after treatment (table 3).

The cpm values and

stimulation indices were similar to those previously
obtained (chapter 3).

There was a slight increase

(P>0.05) in lymphocyte blastogenic responses with johnin
(table 4).

No alterations were found in migration

inhibition before and after treatment (table 5).

No

histologic alterations were seen in sections of ileum and
mesenteric lymph node after treatment (Figures 1-4).

A

marked granulomatous inflammatory reaction in the lamina
propria and submucosa was observed.

Macrophages and

multinucleated giant cells contained variable numbers of
acid-fast bacilli.

Discussion
Treatment with rifabutin produced a positive increase
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in cutaneous delayed hypersensitivity to johnin.

A

possible explanation for this increase is that perhaps
there was an increase in mycobacterial death releasing
internal bacterial antigens important in delayed
hypersensitivity reactions.

An increase in bacterial

death could not be substantiated on the basis of the
tissue sections examined, because only pre- and post
treatment ileum and mesenteric lymph node sections were
examined.

The extent of tissue involvement before

treatment was not determined.

A second explanation may

be that rifabutin itself increased the cutaneous response
by directly affecting lymphocyte or accessory cell
function.

Lastly, it may be that rifabutin had a

bacteriostatic effect resulting in a decrease in
production of soluble substances from mycobacteria which
inhibit skin test reactivity.
The trend of increased lymphocyte blastogenic
responses to johnin may be a reflection of a similar
trend in IL-2 production since IL-2 is known to increase Tcell proliferation in response to mitogen.17

This trend

appears to suggest that cell-mediated immune responses
are being partially restored.

Additional trials with

rifabutin in cattle with paratuberculosis may help to
validate this observation.
The duration and dosage of rifabutin in this
experiment was not sufficient to alter intestinal

and mesenteric lymph node lesions.

A qualitative

assessment indicated a granulomatous inflammatory
response with the presence of numerous acid-fast bacilli
similar to pre-treatment biopsy specimens.
The absorption, deposition and pharmacokinetics of
rifabutin in the ruminant are not known.

These

parameters should also be investigated in order to more
clearly define the value of rifabutin in the treatment of
bovine paratuberculosis.

Table 1.

Delayed Cutaneous Hypersensitivity

In Mycobacterium paratuberculosis-Infected Cattle
Treated With Rifabutin

Pre-Treatment

Post-Treatment

Change in Skin

Change in Skin

Thickness (mm)

Antigen

#1

#2

#3

Thickness (mm)

4.9

johnin

4.4

5.4

10.4

KLH

0.9

0.0

media

0.0

0.1

0.0

0.4

0.2

CM

o
•
U)

3.0

o
•
o

3.9

in
•

5.4

•

3.2

o

3.3

o
•
o

PPD

00
•
00

#3

00
•
(N

#2

o
•
o

#1

mean+SD

mean+SD

PPD

3.97+1.24

3.9 3+0.9 5

johnin

4.20+1.31

8.90+1.45s

KLH

0.30+0.52

0.30+0.10

media

0.03+0.06

0.06+0.12

Table 2.

Mean Con A Blast Proliferative Responses By

Blood Mononuclear Cell Supernatants Containing IL-2
From Mycobacterium paratuberculosi-Infected Cattle
Treated With Rifabutin

Pre-Treatment

Antigen

cpma

Post-Treatment

SIb

cpm

SI

Media

980

1.00

1,113

1.00

PPD

2,341

2.44*

2,177

2.13

johnin

3,870

3.89*

5,805

5.12

KLH

1,015

1.13

1,654

1.39

Con A

9,578

8.79

10,599

9.43

4g

«fp

aRepresents the mean cpm of triplicate assays from
the 3 infected cattle .
the mean.

SD is not greater than 10% of

Only data from the dilution which gave the

highest cpm is shown (1:4).
bThe mean stimulation index was calculated by dividing
the mean of each antigen cpm by the mean of the media
control from each animal.
P<0.05, media comparison.
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Table 3.

Mean Mouse Thymocyte Proliferation By

Monocyte Supernatants Containing IL-1 In The Presence of
Con A From Mycobacterium paratuberculosis-Infected Cattle
Treated with Rifabutin

Pre-treatment

Antigen

cpma

Media

12,654

PPD

SIb

Post-treatment

cpm

SI

1.00

14,166

1.00

11,298

0.93

10,988

0.74

johnin

13,990

1.10

15,011

1.11

KLH

10,512

0.93

12,475

0.88

LPS

25,539

2.13

27,886

2.03

aData expressed is the mean cpm of triplicate assays form
the 3 animals in each group. SD is not greater than 10%
of the mean.

Only data of the dilution which gave the

highest cpm is shown (1:8).
bThe mean lation index (SI) was calculated by dividing
the mean of each antigen cpm by the mean of the nedia
control from each animal.
P<0.05, media comparison.

Table 4.

Mean Lymphocyte Blastogenesis

in Mycobacterium partuberculosis Infected Cattle
Treated With Rifabutin

Pre- treatment

Antigen

Post- treatment

cpm

SIa

cpm

SI

1,008

1.0

1,114

1.0

PPDb

12,499

12.8

14,593

13.2

johnin

10,886

10.3

14,259

11.9

KLHC

3,326

3.6

PHAd

18,547

19.1

media

4,678
21,946

4.6
20.7

aThe mean SI was calculated by dividing the mean antigen
cpm of triplicate assays from each of the 3 infected
animals by the cpm of the media control.

SD did not

exceed 10% of the mean.
^Derived from ML bovis; ckeyhole limpet hemocyanin;
dphytohemaglutinin.
All antigen and mitogen responses are significantly
different than the media control (P<0.05).

No

differences are apparent between pre- and post
treatment data.

Table 5. Mean Percent Inhibition of Migration
In Mycobacterium paratuberculosis-Infected Cattle
Treated With Rifabutin

Antigen

Pre-Treatment

Post-Treatment

PPDb

52.2 + 3.5a*

60.1 + 7.2*

johnin

43.3 + 3.9*

52.7 + 7.9*

KLH

14.2 + 1.8

11.5 + 6.6

aMean+SD.
^Derived from M. bovis.
cKeyhole limpet hemocyanin.
%Migration inhibition exceeded 98% with phytohemaglutinin
in all assays.
Indicates a positive response (>20% inhibition).

Figure 1.
treatment.

Ileal biopsy specimen taken before rifabutin
There is a marked accumulation of macrophages

in the lamina propria and submucosa. HE, 20OX.

Figure 2.

Section of ileum taken adjacent to the initial

biopsy site after rifabutin treatment.

Lesions noted are

similar to the pre-treatment section. HE, 200X.

Figure 3.

Lymph node biopsy specimen taken before

rifabutin treatment.

There is a moderate to marked

accumulation of macrophages in the cortex.

HE, 200X.

Figure 4.

Mesenteric lymph node specimen taken adjacent

to the initial biopsy site after rifabutin treatment.
The section is similar to the pre-treatment biopsy
sample.
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CHAPTER 7

PRELIMINARY STUDIES WITH FERRITIN LABELING
OF BOINE BLOOD MONOCYTES INFECTED WITH MYCOBACTERIUM
PARATUBERCULOSIS

Abstract
Bovine blood monocytes were pulse labeled with
ferritin prior to infection with a field isolate of
Mycobacterium paratuberculosis.

Technical difficulty

most likely related to fixation resulted in the absence
of membranes in the cells examined.

The cells did appear

to phagocytize bacteria and take up the ferritin.
Additional studies to accurately determine phagosomelysosome fusion and killing ability of bovine blood
monocytes is warranted.

Introduction
The intracellular fate of Mycobacterium
paratuberculosis in cultured monocyte/macrophage systems
has been previously examined . ^

These studies have

shown that monocytes and monocyte-derived macrophages are
efficient in phagocytizing the organism but fail to kill
it or prevent its replication.
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Inhibition of phagosome-

lysosome fusion is an important survival mechanism
for several mycobacterial species.

q

in 11

iq

Many of the mononuclear phagocytes seen in the
granulomatous lesions of bovine paratuberculosis probably
represent recently recruited blood monocytes instead of
tissue macrophages.^

This is supported by the finding

that mycobacterial granulomas have a rapid turn-over
rate,^ probably resulting from the influx of blood
monocytes instead of from division of resident
macrophages.3

Blood monocytes may therefore play a

considerable role in the kinetics and maintenance of the
granulomatous lesions in bovine paratuberculosis.

For

this reason, phagosome-lysosome fusion in blood monocytes
infected in vitro with Mycobacterium paratuberculosis was
qualitatively evaluated using ferritin to label
lysosomes.

Materials and Methods
Bacteria.
A field isolate of Mycobacterium paratuberculosis
from a Brahman-cross bovine was
cultured from feces using Herrold's egg-yolk media
containing 2 y.g/ml mycobactin J (Allied Laboratory, Ames,
IA).

Visible bacterial colonies were present after 6

months incubation.

The bacteria was subcultured in

Middlebrook's 7H9 broth supplemented with OADC (Difco

Labs, Detroit, Michigan), Tween 80, and 2 y.g/ml
mycobactin J.

The organism was grown for approximately 4

weeks, harvested by centrifugation, and washed with
phosphate-buffered saline (PBS).

The bacterial pellet

was suspended in 15 ml of PBS and sonicated at 40% power
for 30 seconds (Soni c ator™ Model W-375, Ultrasonics,
Inc.).

The cell suspension was matched to a #4 McFarland

standard equivalent to 12 X 10® bacteria/ml and 1 ml of
cell suspension was added to 3 ml of RPMI 1640 containing
10% fetal bovine serum and 4 mM L-glutamine resulting in
a final concentration of 3 X 10®bacteria/ml.

Viability

was assessed at >95% by fluorescein diacetate-ethidium
bromide s t a i n i n g . 5

Preparation of Cells
Heparinized venous blood (30 ml) from a healthy
adult cow was diluted approximately in half with PBS and
layered onto 1.080 g/ml Ficoll 400-Sodium diatrizoate
(Histopaque, Sigma Chemical Co., St. Louis, Missouri).
The blood and Ficoll gradient was centrifuged at 1000 X g
for 45 minutes. The mononuclear cell layer removed and
washed 3 times in PBS.

Cell concentration was adjusted

to 5 X 10® cells/ml in RPMI supplemented with 10% fetal
bovine serum and 4mM L-glutamine.

The cells were allowed

to adhere in a 60 mm plastic petri dish for 1 hr.

Non

adherent cells were washed off and the adherent cell

layer removed by scraping and adjusted to 1 X 106 cells
in media.

The cell suspension (3 ml) was allowed to re-

adhere in a 60 mm petri dish for 1 hr before ferritin
labeling.

Ferritin Labeling
A ferritin (equine spleen) solution (20 mg/ml)
(Sigma Chemical Co., St. Louis, Missouri) was prepared in
PBS containing 2% fetal bovine serum.

The media from the

adherent cells was removed and stored in a sterile
container.

The ferritin solution (4 ml) was added to the

petri dish containing the cells and incubated at 37°C for
3 hrs in the presence of 5% CO2 .

The ferritin solution

was removed and the cells washed 3 times with PBS.

The

original culture media was then returned to the petri
dish and incubated an additional 3 hrs.

Addition of Bacteria to Monocytes
The bacterial suspension (2 ml), as described above,
was added to the cells and incubated for 3 hrs.

After

incubation, non-phagocytized bacteria were removed by
washing with PBS.

Electron Microscopy
The adherent cells were fixed to the petri dish with
cold 3% glutaraldehyde in 0.1% sodium cacodylate buffer

(pH = 7.4) for one hour.

The cells were then removed by

scraping from the petri dish, washed twice in 0.1 M
cacodylate buffer containing 5% sucrose, and gently
pelleted at 200 X g.

One drop of melted 4% agarose was

added to the cell pellet and gently mixed.

The agarose

was allowed to harden and was minced into < 1mm cubes.
Post fixation was performed with 1% 0s04 in 0.1M
cacodylate buffer (pH = 7.4) for one hour followed by
dehydration in graded alcohols and propylene oxide.
Infiltration and embedding was in Spurr's resin.

Thin

sections (60nm) were placed on uncoated copper grids and
stained with uranyl acetate.

The sections were viewed on

a Zeiss EM-109 transmission electron microscope (Carl
Zeiss Inc., Oberkochen, West Germany).

Results
Ferritin and bacteria were visible in all of the
cells examined.

No monocyte or bacteria-associated

membranes were visible.

The majority of the ferritin was

present in round clumps, probably representing secondary
lysosomes, and in vacuoles which also contained bacteria
(Figures 1-4).

Discussion
Although ferritin labeling techniques for marking
secondary lysosomes and morphologic evaluation of

phagosome-lysosome fusion has recently been
criticized,1 2 '12 d'Arcy Hart has provided a good defense
for its use.7

The growth of intracellular parasites,

such as Listeria monocytogenes,6 Legionella
pneumophilia,

and Toxoplasma gondii,20

is poor in

monocytes, however, other studies indicated that blood
monocytes and monocyte-derived macrophages supported the
91

intracellular growth of Mycobacterium paratuberculosis,
although macrophages by virtue of increased protein and
lysozomal enzymes and increased phagocytic capacity are

considered to be more effective than monocytes as killing
cells in infectious granulomatous diseases.1 0 '22
The methods used to process and stain the cells in
this study did not allow accurate visualization of cell
membranes.

Therefore the formation of a true peri-

bacillary electron transparent zone and phagosomelysosome membrane fusion was not be assessed.

This zone

has been seen in macrophages infected with a variety of
mycobacteria including M^_ leprae,10 M. tuberculosis.^ M.
lepraemurium,2 M. avium,11 and M.
paratuberculosis.17,18,21

j^g been interpreted that

It has been suggested that some bacterial surface
component is responsible for the formation of the
electron transparent zone and that this zone may
represent a defense mechanism for intracellular survival
of the bacilli.0 '9

Recently evidence indicates that this

zone is probably not produced by bacterial surface
components because coating the organism with immune sera
does not inhibit formation of the zone.
The kinetics and morphogenesis of mycobacterial
granulomas appears variable, but mycobacterial granulomas
in general are considered to have a rapid turnover rate.
Development into epitheliod lesions may require 4 to 22
days depending upon the mycobacteria responsible for the
lesion.1

High turnover granulomas have been described as

being caused by non-toxic materials, and the macrophages
contain relatively small amounts of the agent.

This is

the case in BCG and M;_ tuberculosis granulomas, but
not in paratuberculosis.

The lesions of paratuberculosis

consist of epithelioid cells and giant cells which
contain large numbers of bacteria.

This is more

indicative of low turnover granulomas.1
It would be interesting to speculate that fresh blood
monocytes are active in phagosome-lysosome fusion and
killing of

paratuberculosis.

This would account for

prevention of bacterial dissemination and localization of
the infection to the intestine and regional lymph nodes.
These hypotheses can not be tested adequately until
better morphologic and cultural data is obtained.
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Figure 1.

The electron dense ferritin is present as

round symmetrical clumps within the cell.
acetate.)

(Uranyl
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Figure 2.

The ferritin appears as fine grains in what

may be a phagocytic vacuole.

(Uranyl acetate).
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mmmM

Figure 3.

A clump of ferritin adjacent to a structure

resembling a bacterium.

(Uranyl acetate)
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CHAPTER 8

CONCLUSIONS AND SUMMARY

Cattle with chronic paratuberculosis had positive
lymphocyte blastogenic (LB) and migration inhibition
factor (MIF) assay results using johnin and M^_ bovis PPD.
This indicated that these cattle have the ability to
respond immunologically to these related antigens.

The

LB and MIF assay responses with johnin in infected cattle
were similar to non-infected cattle after sensitization
with WL_ paratuberculosis bacterin.

This suggested that

the in vitro response using these assays was of a normal
magnitude.

Infected cattle, in contrast to non-infected

cattle, failed to develop positive skin tests and LB and
MIF assay responses to keyhole limpet hemocyanin (KLH)
after administration of a sensitizing dose of KLH in
Freund's incomplete adjuvant.

This lack of dermal

response may have been related to the dose of KLH used or
the minimum time allowed for a positive response to
develop.

Infected cattle apparently have the ability to

respond immunologically to specific or cross-reactive
antigen, yet fail to respond to a potent heterologous
antigen.

Failure of KLH responsiveness was not due to
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inherent defects in mononuclear cell proliferation
capacity as demonstrated by a positive response to
mitogen-induced proliferation.

Sensitization of infected

cattle with homologous antigen did not alter LB and MIF
assay responses detected before sensitization.

This

indicated an uninducible steady-state of reactivity to M.
paratuberculosis antigens.

Skin test reactivity to

johnin and M^ bovis PPD was significantly decreased by
administration of

paratuberculosis bacterin.

It

appeared that the cell type responsible for a positive
skin test was made unreactive by high-dose antigen
tolerance (desensitization).
Preliminary evidence suggested that phagosomelysosome fusion in cultured blood monocytes may be
assessed by pulse labeling with ferritin.

The results

obtained initially did not allow adequate interpretation,
but suggested that phagosome-lysosome fusion had taken
place.

Additional studies using ferritin labeling

appeared warranted.
Treatment of infected cattle with rifabutin
significantly increased skin test reactivity to johnin.
The reason for this may be that rifabutin damaged the
bacilli and released previously hidden sensitizing
antigens important in delayed hypersensitivity reactions.
Damaged bacilli may have decreased their capacity to
produce soluble substances which inhibit delayed
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hypersensitivity reactions.

It may also be speculated

that rifabutin had a direct effect on the cells
responsible for cutaneous hypersensitivity.

Although no

significant differences in interleukin-1 (IL-1) release,
interleukin-2 (IL-2) production, and LB and MIF assays
were noted after rifabutin treatment, trends suggested
that these parameters were increasing.

Beneficial

results may be obtained by longer treatment duration
and/or a different dosage regimen.
The production of IL-2 by peripheral blood
mononuclear cells induced by concanavalin A was
significantly suppressed in infected cattle.

These

cattle produced significant levels of IL-2 in response to
johnin and ML bovis PPD which was unaltered after
administration of sensitizing doses of these antigens.
Interleukin-2 production in response to KLH could not be
induced by sensitizing doses of KLH in Freund’s
incomplete adjuvant.

Control cattle produced

significantly greater amounts of IL-2 than infected
cattle after sensitization.

This indicated a defective

IL-2 production mechanism in infected cattle.

It can be

speculated that this defect in IL-2 production results in
inadequate numbers of
lymphocytes.

paratuberculosis-reactive

Without reactive lymphocytes, killer cell

and macrophage activation does not occur (discussed in
Chapter 4).

This may account for disease persistence in
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paratuberculosis.
Augmentation of lymphocyte function in infected
cattle by specific transfer factor to KLH and M.
paratuberculosis resulted in positive MIF assay responses
and increased IL-2 production to these antigens.

The

ability of transfer factor to increase IL-2 production in
response to specific antigens has not been previously
reported.
Blood monocytes from infected spontaneously released
high levels of IL-1 in the absence of antigenic or
mitogenic stimulus.

There is no direct evidence that

indicates that monocytes or macrophages in the lesions
react similarly.

The spontaneous release of IL-1 by

blood monocytes probably results from a chronic state of
activation of these cells induced by mycobacterial
products.

There may also be a defective IL-1 regulatory

mechanism in infected cattle.

Whether this IL-1 detected

by in vitro assays is a functional lymphocyte activating
monokine in vivo is not known.

It could be speculated

that some of the clinical signs seen in infected
cattle,such as cachexia, muscle wasting, and
neutrophilia, might be attributed to high systemic levels
of IL-1.
On the basis of the information gathered in this
study the principle immunologic defect in chronic bovine
paratuberculosis appeared to be a decreased ability to

produce IL-2 and that this defect is at the level of the
T-lymphocyte.

A potential failure to regulate IL-1

release in blood monocytes was also discovered.
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